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Abstract N-myristoylation is a ubiquitous class of protein lipidation across eukaryotes and N-
myristoyl transferase (NMT) has been proposed as an attractive drug target in several pathogens.
Myristoylation often primes for subsequent palmitoylation and stable membrane attachment,
however, growing evidence suggests additional regulatory roles for myristoylation on proteins.
Here we describe the myristoylated proteome of Toxoplasma gondii using chemoproteomic
methods and show that a small-molecule NMT inhibitor developed against related Plasmodium
spp. is also functional in Toxoplasma. We identify myristoylation on a transmembrane protein, the
microneme protein 7 (MIC7), which enters the secretory pathway in an unconventional fashion with
the myristoylated N-terminus facing the lumen of the micronemes. MIC7 and its myristoylation play
a crucial role in the initial steps of invasion, likely during the interaction with and penetration of the
host cell. Myristoylation of secreted eukaryotic proteins represents a substantial expansion of the
functional repertoire of this co-translational modification.
Introduction
Toxoplasmosis currently affects approximately one third of the world’s population (Robert-
Gangneux and Dardé, 2012). It is caused by the obligate protozoan parasite Toxoplasma gondii
originating from the phylum Apicomplexa. While the majority of human infections are asymptomatic,
the disease manifests its severity in immunocompromised individuals, such as those receiving chemo-
therapy and transplants or in HIV/AIDS patients (Montoya and Liesenfeld, 2004). Key steps in the
successful propagation of Toxoplasma infection in the acute phase are orchestrated cycles of inva-
sion and egress of tachyzoites from host cells (Black and Boothroyd, 2000). These crucial processes
are regulated by several post-translational modifications (PTMs), such as phosphorylation
(Gaji et al., 2015; Jacot and Soldati-Favre, 2012; Lourido et al., 2010; Treeck et al., 2014), ubiq-
uitination (Silmon de Monerri et al., 2015), and also protein lipidation, such as palmitoylation and
myristoylation (Alonso et al., 2012; Frénal et al., 2014).
While the extent of protein palmitoylation in Toxoplasma has been investigated (Caballero et al.,
2016; Foe et al., 2015), the myristoylated proteome remains largely uncharacterised. N-
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myristoylation is an irreversible, predominantly co-translational covalent addition of myristic acid to
an N-terminal glycine (Boutin, 1997; Gordon et al., 1991). Functionally, myristoylation often primes
proteins for subsequent palmitoylation and a stable protein-membrane association (Martin et al.,
2011; Wright et al., 2010), however, it has also been shown to facilitate protein-protein interactions
(PPIs) (Chow et al., 1987; Mousnier et al., 2018), affect protein activity (Zhu et al., 2019) as well as
structure and stability (Zheng et al., 1993). It is catalysed by N-myristoyl transferase (NMT), which is
conserved across many organisms, including Toxoplasma, and has been reported to be a prominent
drug target in fungal (Devadas et al., 1995; Nagarajan et al., 1997), Trypanosome (Frearson et al.,
2010; Wright et al., 2016) and Leishmania infections (Hutton et al., 2014; Wright et al., 2015). In
Plasmodium falciparum (the major causative agent of malaria), inhibition of NMT leads to severe
pleiotropic consequences affecting parasite development (Schlott et al., 2019; Wright et al.,
2014), highlighting the importance of myristoylation for parasite survival and progression.
An N-terminal glycine (MG motif) is a requirement, but not a predictor of myristoylation. Approxi-
mately 6% of all gene products in Toxoplasma contain an N-terminal glycine and an in silico predic-
tion of myristoylation suggests that ~ 1.8% of all T. gondii gene products are modified
(Alonso et al., 2019). The functional significance of myristoylation has been described for only a few
T. gondii proteins, and mainly in conjunction with adjacent palmitoylation that promotes stable
membrane attachment. These proteins include key signal mediators in parasite egress and invasion,
for example CDPK3 (Garrison et al., 2012; McCoy et al., 2012), PKG (Brown et al., 2017), PKAr
(Jia et al., 2017b; Uboldi et al., 2018); proteins involved in invasion, for example IMP1 (Jia et al.,
2017a); parasite gliding, for example GAP45 and GAP70 (Frénal et al., 2010); division, for example
F-box protein 1 and ISP1, 2, 3 (Baptista et al., 2019; Beck et al., 2010); and correct rhoptry posi-
tioning required for invasion, for example ARO (Cabrera et al., 2012; Mueller et al., 2013). Collec-
tively, these studies show key roles for myristoylation throughout the parasite’s lytic cycle, but the
function of myristoylation in the absence of palmitoylation and its relationship to other PTMs remains
poorly described.
eLife digest A microscopic parasite known as Toxoplasma gondii infects around 30% of the
human population. Most infections remain asymptomatic, but in people with a compromised
immune system, developing fetuses and people infected with particular virulent strains of the
parasite, infection can be fatal. T. gondii is closely related to other parasites that also infect humans,
including the one that causes malaria. These parasites have complex lifecycles that involve
successive rounds of invading the cells of their hosts, growing and then exiting these cells. Signaling
proteins found at specific locations within parasite cells regulate the ability of the parasites to
interact with and invade host cells. Sometimes these signaling proteins are attached to membranes
using lipid anchors, for example through a molecule called myristic acid.
An enzyme called NMT can attach myristic acid to one end of its target proteins. The myristic
acid tag can influence the ability of target proteins to bind to other proteins, or to membranes.
Previous studies have found that drugs that inhibit the NMT enzyme prevent the malaria parasite
from successfully invading and growing inside host cells. The NMT enzyme from T. gondii is very
similar to that of the malaria parasite. Broncel et al. have shown that the drug developed against P.
falciparum also inhibits the ability of T. gondii to grow. These findings suggest that drugs against
the NMT enzyme may be useful to treat diseases caused by T. gondii and other closely-related
parasites.
Broncel et al. also identified 65 proteins in T. gondii that contain a myristic acid tag using an
approach called proteomics. One of the unexpected ‘myristoylated’ proteins identified in the
experiments is known as MIC7. This protein was found to be transported onto the surface of T.
gondii parasites and is required in its myristoylated form for the parasite to successfully invade host
cells. This was surprising as myristoylated proteins are generally thought to not enter the pathway
that brings proteins to the outside of cell.
These findings suggest that myristic acid on proteins that are secreted can facilitate interactions
between cells, maybe by inserting the myristic acid into the cell membrane.
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By combining several chemoproteomic tools for substrate identification with a small-molecule
NMT inhibitor, we provide experimentally-validated libraries of myristoylated as well as glycosyl-
phosphatidylinositol (GPI) anchored proteins in T. gondii. We identify all the previously reported
myristoylated proteins, as well as novel substrates with heterogeneous localisations and variable
functions across the lytic cycle. Furthermore, by analysing substrate orthology in other Apicomplex-
ans we provide new clues to the identity of previously uncharacterized myristoylated proteomes
across the phylum. We validate the presence and elucidate the functional importance of myristoyla-
tion for the microneme protein MIC7, a predicted type I transmembrane protein. Utilizing condi-
tional substrate depletion and complementation with wild-type (cWT) and myristoylation mutant
(cMut) versions, we demonstrate that myristoylation of MIC7 is functionally important in host cell
invasion. Taken together, our study identifies a large proportion of the Toxoplasma myristoylated
proteome and points to unexpected and novel functions of myristoylation in Toxoplasma that extend
beyond priming for palmitoylation and stable membrane attachment.
Results
Metabolic labelling allows for enrichment and visualisation of
myristoylated and GPI-anchored proteins in Toxoplasma
To visualise the extent of myristoylation in Toxoplasma, we adapted a metabolic labelling approach
that has previously been applied to mammalian cells (Broncel et al., 2015; Thinon et al., 2014) and
protozoan parasites (Wright et al., 2014; Wright et al., 2016; Wright et al., 2015). In this work-
flow, a myristic acid (Myr) analogue containing a terminal alkyne group (YnMyr) is added to cell cul-
ture upon infection with Toxoplasma tachyzoites (Figure 1A). The hydrophobic nature of YnMyr
allows for optimal biomimicry of myristate and conversion into the active co-substrate YnMyr-CoA in
situ, while the alkyne tag allows for NMT-mediated metabolic labelling of both host and parasite
substrate proteins. Upon cell lysis, labelled proteins are liberated and conjugated to azide-bearing
multifunctional capture reagents by a click reaction (Heal et al., 2012). The conjugation process
introduces secondary labels, like biotin and fluorophores, allowing for substrate enrichment on strep-
tavidin beads and visualisation via in-gel fluorescence (igFL), respectively. To investigate the extent
of YnMyr incorporation, intracellular tachyzoites were treated with either Myr or increasing concen-
trations of YnMyr for 16 hr. Within this timeframe protein labelling in vivo did not appear to exert
any toxic effects on Toxoplasma parasites. Labelled proteins were then conjugated to a capture
reagent and resolved by SDS-PAGE. As visualised by igFL, the labelling was concentration-depen-
dent with only negligible background (Figure 1—figure supplement 1A). In addition, the extent of
labelling did not seem to depend on parasite localisation inside or outside the host cell, and was effi-
ciently out-competed by excess myristate, indicating that YnMyr is an effective mimic of myristate in
Toxoplasma parasites (Figure 1—figure supplement 1B). To estimate the efficiency of substrate
enrichment, we took advantage of the biotin moiety that enables a streptavidin-based pull down.
Using igFL as readout we observed robust enrichment of protein substrates in a YnMyr-dependent
manner, and detected very little background in controls (Figure 1—figure supplement 1C).
It has been reported that in Plasmodium parasites, YnMyr can be incorporated not only at N-ter-
minal glycines via amide bonds, but also through ester-linked incorporation of myristate into GPI
anchors (Wright et al., 2014). These two distinct types of labelling can be readily distinguished by
their different sensitivity to base treatment; amide bonds are stable in basic conditions, whereas
ester bonds are hydrolysed. To visualise the extent of YnMyr incorporation into GPI anchors in Toxo-
plasma, we performed base treatment prior to enrichment of substrate proteins and observed a
reduction of igFL signal for selected enriched bands (Figure 1B). To further validate the base treat-
ment approach, we probed known N-myristoylated and GPI-anchored Toxoplasma proteins, GAP45
and SAG1, for their ability to be enriched in a base-dependent manner. In the absence of treatment,
both proteins were robustly pulled down with YnMyr, while upon base treatment, only GAP45
remained enriched, confirming that it is a true myristoylation substrate (Figure 1C). Collectively, we
confirmed that YnMyr is a robust and high-fidelity myristate analogue and demonstrated that it can
be applied to profile both N-myristoylated and GPI-anchored proteins in live T. gondii.
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Proteomic identification of YnMyr-enriched proteins in T. gondii
To confidently identify YnMyr-labelled proteins in Toxoplasma, we applied state-of-the-art
mass spectrometry (MS)-based proteomics combined with validated chemical tools (Figure 2—fig-
ure supplement 1A); (Broncel et al., 2015; Speers and Cravatt, 2005; Thinon et al., 2014;
Wright et al., 2014). We started with a small-scale pilot experiment to test our workflow and differ-
entiate between N-myristoylation-based enrichment and GPI-anchored substrates. We metabolically
labelled intracellular tachyzoites of the RH strain (Huynh and Carruthers, 2009) with either YnMyr
or Myr each at 25 mM for 16 hr. We then lysed the infected cell monolayers and performed the click
reaction with the azido biotin capture reagent (reagent 1) to facilitate YnMyr-dependent enrichment
of labelled proteins. To distinguish myristoylated from GPI-anchored substrates, we applied base
treatment prior to the streptavidin-based pull down. Following trypsin digestion, we analysed sam-
ples by LC-MS/MS and performed label free quantification (LFQ) of enriched proteins. We quantified
2363 human and Toxoplasma proteins, 349 of which were parasite proteins with YnMyr intensities
irrespective of base treatment (Supplementary file 1). To identify GPI-anchored proteins, we calcu-
lated log2 fold changes between base-treated and untreated samples. To threshold we utilised the
Figure 1. Metabolic labelling allows for enrichment and visualisation of myristoylated and GPI-anchored proteins in T. gondii. (A) Metabolic labelling
workflow. (B) In gel fluorescence visualisation of YnMyr-dependent enrichment without and with the base treatment (top) and western blot with a-SFP1
(TGGT1_289540) showing the loading control (bottom). (C) Western blot analysis of YnMyr-dependent pull down for known myristoylated and GPI-
anchored proteins GAP45 and SAG1, respectively. White space was used to indicate where gel lanes were not contiguous. See also Figure 1—figure
supplement 1.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. Metabolic labelling optimisation.
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least extreme negative value (log2 fold change <  1) quantified from all Surface Antigen Proteins
(SAGs) detected in our study, which are known to be GPI-anchored (Figure 2—figure supplement
1B). This selection strategy yielded 52 substrates, that included known and predicted GPI-anchored
proteins (Supplementary file 1). To identify myristoylated proteins we utilised a stringent selection
method based on three criteria: a) robust YnMyr/Myr enrichment (log2 fold change > 2) with thresh-
old selected based on known myristoylated proteins (Figure 2—figure supplement 1C), b) the pres-
ence of an MG motif and c) insensitivity to base treatment. 56 proteins met these criteria, including
those previously reported as myristoylated (Supplementary file 1). Analysis of post enrichment
supernatants did not reveal any substantial changes between proteomes of the YnMyr- and Myr-
treated samples, confirming that the observed enrichment is not due to globally altered protein
abundance (Figure 2—figure supplement 1D and Supplementary file 1).
After successful testing of the metabolic labelling workflow, we performed a more elaborate MS
experiment using cleavable capture reagents bearing either trypsin (reagent 2) or TEV (reagent 3)
cleavable linkers (Figure 2—figure supplement 1A). In contrast to a non-cleavable reagent (e.g.
reagent 1) that provides only indirect proof of substrate myristoylation, cleavable reagents allow for
detection of myristoylated peptides in addition to peptides that originate from the enriched proteins
(Figure 2A). This additional layer of confidence in MS-based substrate identification is especially
important given the high level of non-myristoylation dependent background reported for metabolic
labelling with YnMyr (Broncel et al., 2015; Wright et al., 2016; Wright et al., 2015). While
reagent 2 has been validated as a tool for myristoylated protein and peptide discovery
(Broncel et al., 2015), reagent 3 (Speers and Cravatt, 2005), which is expected to produce less
background and improve myristoylated peptide discovery, has not previously been applied to study
protein myristoylation. We therefore first tested reagent 3 in terms of YnMyr-dependent protein
enrichment and observed robust pull down of potential NMT substrates (Figure 2—figure supple-
ment 1E). We next generated samples for the MS workflow as described above but, instead of con-
jugating reagent 1, we conjugated either 2 or 3, each in biological triplicate, to labelled proteins via
click reaction to enable myristoylation-dependent pull down. As depicted in Figure 2A, reagent 2
requires only a single trypsin digestion step to liberate both unmodified and myristoylated peptides
in one pool. By contrast, reagent 3 requires both trypsin and TEV protease digestion and, depend-
ing on the enzyme combination, releases unmodified and myristoylated peptides in either one (TEV
I) or two (TEV II) separate fractions (Figure 2A). In the TEV I strategy TEV protease is used to cleave
proteins from beads followed by trypsin digestion of proteins into peptides. The cleavage will only
occur for proteins bound via the TEV linker and not for the non-specifically bound ones, which
should significantly reduce background. In the TEV II strategy, trypsin is used first to remove most
proteins from the beads, only retaining the captured myristoylated peptides. These are then specifi-
cally released using TEV protease cleavage resulting in much reduced sample complexity, which
increases the myristoylated peptide discovery by MS. Following digestion, all samples were sub-
jected to LC-MS/MS, and LFQ was performed to identify proteins robustly enriched in YnMyr-depen-
dent manner. This yielded 206 human and 117 T. gondii proteins bearing an N-terminal MG motif
(Supplementary file 2). Within the parasite protein pool, we obtained statistically significant (FDR
1%, log2 fold change >2) enrichment in YnMyr over Myr controls for 72 potential substrates using
reagent 2 (Supplementary file 2). For reagent 3, which was used in two different scenarios (TEV I
and TEV II) resulting in larger variability between replicates, we utilised a fold change based thresh-
old (log2 fold change >2) and obtained 48 robustly enriched proteins (Supplementary file 2). Reas-
suringly, we observed a ~ 5 and~8 fold reduction in background in TEV I vs TEV II and TEV I vs
reagent 2, respectively, as shown by the number of proteins quantified in Myr controls
(Supplementary file 2). Collectively we identified 76 significantly YnMyr-enriched proteins utilizing
reagents 2 and 3 with an overlap of 60% (Figure 2B, Supplementary file 2) which provides substan-
tial confidence to the accuracy of our results. Application of the same selection criteria to 206 human
MG proteins identified in our study yielded 102 potential substrates. 84 of these proteins have previ-
ously been reported as myristoylated (Broncel et al., 2015; Castrec et al., 2018; Thinon et al.,
2014), which further strengthens our substrate identification strategy.
We next focused on the identification of myristoylated peptides in samples processed with
reagents 2 and 3. Using stringent criteria for the unbiased identification of the myristoylation adduct,
as well as manual validation of the acquired MS/MS spectra, we identified 31 myristoylated peptides
(Supplementary file 2), 24 of which were detected using reagent 2, and 20 using reagent 3
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(Figure 2C). None of these peptides were detected in Myr controls, and the myristoylation adduct
was not identified on cysteine residues. Despite almost equal numbers of peptides detected by the
two reagents, the overlap was only 40% (Figure 2C), confirming the added value of orthogonal
methods for modified peptide detection. As envisioned in our design strategy, we obtained an
increase in myristoylated peptide discovery in TEV II (17) vs TEV I (12) workflow (Figure 2—figure
supplement 1F).
Finally, to summarise our global proteomic study, we combined our results on both protein
enrichment and the modified peptide levels. We filtered for proteins identified with at least two of
three capture reagents or proteins for which we detected a lipid modified peptide. This resulted in
Figure 2. Identification of the YnMyr-enriched proteome in T. gondii. (A) Schematic representation of the MS workflow using non-cleavable and
cleavable capture reagents. (B) Venn diagram illustrating the overlap between significantly YnMyr-enriched proteins identified with capture reagents 2
and 3. The number of significantly enriched proteins per reagent and in total is given in parenthesis. (C) Venn diagram showing the overlap in
myristoylated peptide discovery between the two cleavable capture reagents used in this study. The number of modified peptides identified with each
reagent and in total is given in parenthesis. (D) Label free quantification of the log2 fold changes in YnMyr enrichment over the Myr control plotted
against the statistical significance for all parasite proteins detected in this study using reagent 2. Proteins with N-terminal glycine and significant, base-
insensitive enrichment with at least two capture reagents are highlighted in blue and red subject to the presence of a myristoylated peptide. All other
identified proteins (YnMyr-enriched with only one reagent, background and GPI-anchors) are represented in grey. See also Figure 2—figure
supplement 1, Supplementary file 1 and Supplementary file 2.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Identification of the YnMyr-enriched proteome in T. gondii.
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65 proteins, of which 48% have direct MS/MS evidence for protein myristoylation
(Supplementary file 2, Figure 2D).
Chemical inhibition of TgNMT
Given that our global proteomic screen provided direct proof for substrate myristoylation for
approximately 50% of selected proteins, we sought for an alternative strategy for substrate valida-
tion using NMT inhibitors (NMTi). Here, parasites are treated with NMTi to specifically reduce the
incorporation of YnMyr into nascent proteins, which can be quantified by MS (Thinon et al., 2014;
Wright et al., 2014; Wright et al., 2016; Wright et al., 2015). In the absence of a dedicated
TgNMTi, we used IMP-1002, a compound recently shown to inhibit NMT of Plasmodium falciparum
(Schlott et al., 2019) which is related to Toxoplasma. Homology modelling (SWISS-MODEL,
[Waterhouse et al., 2018]) of the TgNMT sequence onto the available Plasmodium vivax (another
important malaria causing Plasmodium spp.) NMT crystal structure with bound IMP-1002 (PDB:
6MB1, [Schlott et al., 2019]) revealed high sequence identity (57%) and showed that all residues
directly involved in compound binding are conserved within the TgNMT active site and therefore
predicted to adopt an identical structural arrangement (Figure 3A). We therefore reasoned that
IMP-1002 should also inhibit TgNMT. To test this, we co-treated intracellular parasites 16 hr post
invasion with YnMyr and increasing concentrations of the inhibitor for 5 hr and analysed the effects
on YnMyr labelling of Toxoplasma proteins. A dose-dependent drop in igFL labelling of most pro-
tein bands was observed and further confirmed by specifically probing for CDPK1, a substrate identi-
fied herein (Figure 3B). Consistent with TgNMT inhibition, CDPK1 pull down was reduced with
increasing inhibitor concentrations. This was not a general reduction of protein levels as shown by
anti-Toxoplasma antibodies. Plaque assays in the presence of inhibitor showed dose-dependent kill-
ing of parasites, suggesting that treatment with IMP-1002 has severe consequences for the in vitro
expansion of the tachyzoite population but not for the host cells which appeared unaffected
(Figure 3C).
Having confirmed target engagement with IMP-1002, we next performed a large-scale MS-based
inhibitor response analysis. Intracellular parasites were fed with 25 mM YnMyr alone or co-incubated
with 0.05 mM and 0.5 mM NMTi in biological triplicates. Samples were then clicked, pulled down and
the level of protein myristoylation in response to IMP-1002 quantified by MS and LFQ. No major
effect was observed for the lower concentration of the inhibitor, therefore we performed statistical
analysis between triplicate samples treated with either only YnMyr, or YnMyr + 0.5 mM NMTi. We
identified a statistically significant (FDR 5%, log2 fold change > 0.5) response for 56 proteins
(Figure 3D, Supplementary file 3). Analysis of total proteomes from inhibited samples confirmed
that the observed substrate response was not due to the altered protein abundance (Figure 3—fig-
ure supplement 1, Supplementary file 3). 49 significant responders contained the MG motif with
47 of these being significantly enriched in our previous experiment, while two proteins were not
quantified. Specific dose-responses were plotted for selected proteins identified previously as signif-
icantly YnMyr-enriched (Figure 3E). While most showed a robust response to the highest concentra-
tion of inhibitor, CDPK3 and PKG did not, despite substantial literature evidence for myristoylation
(Brown et al., 2017; Garrison et al., 2012; McCoy et al., 2012), including the presence of a myris-
toylated peptide in case of CDPK3 (Supplementary file 2). In fact, a total of 7 proteins for which the
myristoylated peptide was detected did not respond robustly to NMT inhibition
(Supplementary file 3). This behaviour is surprising, however a similar observation has been
described for other organisms (Thinon et al., 2014; Wright et al., 2014; Wright et al., 2016;
Wright et al., 2015) and could be due to low protein turnover, higher affinity for NMT, or potential
interference from other modifications, such as protein S-acylation for example. A further seven pro-
teins for which we obtained myristoylated peptides were not quantified at the highest concentration
of IMP-1002 (Supplementary file 3), suggesting that their myristoylation state, and therefore enrich-
ment, is most affected by NMT inhibition.
A significant response to NMTi was also observed for seven proteins that did not contain the MG
motif (Figure 3D, Supplementary file 3). This could be due to post-translational myristoylation
where proteolysis results in formation of N-terminal glycine (Martin et al., 2011; Thinon et al.,
2014), a tight association in complex with an NMT substrate (Thinon et al., 2014), potential protein
mis-annotation or an off-target effect of the inhibitor which was originally designed for PfNMT.
Importantly, all non MG proteins previously assigned as sensitive to base treatment, including all
Broncel et al. eLife 2020;9:e57861. DOI: https://doi.org/10.7554/eLife.57861 7 of 38
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Figure 3. Chemical inhibition of TgNMT and substrate response. (A) Prediction of IMP-1002 interaction with TgNMT based on the PvNMT crystal
structure. Crystal structure of the PvNMT (PDB: 6MB1, Schlott et al., 2019) active site (orange, red text) with IMP-1002 inhibitor bound, overlaid with a
TgNMT model (cyan, blue text). Hydrogen bonds between key PvNMT residues (Serine and Leucine) and IMP-1002 are shown as black dashes. (B)
Analysis of the dose response to IMP-1002 via igFL and by western blotting with CDPK1 – a substrate identified in this study. (C) Plaque assay
Figure 3 continued on next page
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SAG proteins, showed no significant response to inhibitor (Supplementary file 3, Figure 3F) thus
validating base sensitivity as a means to distinguish YnMyr incorporation at N-terminal glycines or
GPI anchors.
Finally, despite no apparent effect on host cells in plaque assays (Figure 3C), we also observed a
certain level of response to IMP-1002 for host proteins (Supplementary file 3). This suggests that
human NMT is also targeted by this compound, however, without visible impact on the integrity of
the monolayer of host cells.
The myristoylated proteome of Toxoplasma
To generate a comprehensive list of myristoylated proteins in Toxoplasma, we combined YnMyr
enrichment with the substrate response to NMT inhibition and the myristoylated peptide discovery.
This stringent selection strategy yielded 65 substrates that were further split based on the confi-
dence level (Supplementary file 4). 42 substrates were classified as high confidence (the presence
of myristoylated peptide and/or robust response to NMT inhibition with YnMyr enrichment  two
capture reagents) while 19 were classified as medium confidence (the presence of myristoylated
peptide or response to NMT inhibition with YnMyr enrichment with one capture reagent). Finally,
PKG and PPM5C that did not pass our confidence criteria, yet have been reported as myristoylated
by others (Brown et al., 2017; Yang et al., 2019), as well as two proteins that responded to NMT
inhibition, yet were not present in our global enrichment analysis, were classified as lower confidence
hits (Supplementary file 4). Our substrate list includes all proteins previously reported as myristoy-
lated, which validates our approach and indicates that this analysis covers a large fraction of the myr-
istoylated proteome in Toxoplasma. Notably, in silico prediction for myristoylation (Alonso et al.,
2019) disagreed with 11 of our high and medium confidence substrates (Supplementary file 4). This
is not necessarily surprising, given that the prediction was based on a consensus myristoylation
sequence derived from other organisms (Martin et al., 2011), and highlights the importance of
experimental validation of NMT substrates.
90% of our substrate pool represent novel substrates of TgNMT. Several of these proteins have
previously been shown to play important functions across the lytic cycle, for example CDPK1
(egress/invasion; [Lourido et al., 2010]); PPM5C (attachment; [Yang et al., 2019]); ARF1 and Rab5B
(trafficking; [Kremer et al., 2013; Liendo et al., 2001]). Others, for which the precise function has
yet to be discovered, were assigned by gene ontology into key functional classes, like kinases, phos-
phatases, hydrolases and protein binding (Supplementary file 4). We did not obtain any evidence
for myristoylation on known secreted Toxoplasma proteins, such as rhoptry or dense granule pro-
teins, indicating that these are not substrates of host NMT after secretion. Approximately one third
of the reported substrates are uncharacterized proteins, indicating that a large amount of myristoyla-
tion-related biology is still to be uncovered.
As expected, the identified substrates showed heterogeneous localisation (Figure 4A). Utilizing
the localisation of organelle proteins by isotope tagging (LOPIT) prediction (Barylyuk et al., 2020)
within ToxoDB (Gajria et al., 2008), we found proteins from key cellular organelles, including the
nucleus, mitochondrion, proteasome and micronemes. In agreement with the functional relevance of
myristoylation, we found 50% substrates with known or predicted localisation at the plasma mem-
brane (PM), as well as membrane-bound compartments (e.g. inner membrane complex (IMC), endo-
plasmic reticulum (ER), and Golgi apparatus). Stable attachment at membranes may require a
double acylation, that is both myristoylation and palmitoylation (Wright et al., 2010), however, only
Figure 3 continued
illustrating differential killing of parasites and the host cells. The assay was performed for 5 days in three biological replicates, each in technical
triplicate, representative images are shown. (D) Label free quantification of the YnMyr label incorporation into proteins in the presence of NMTi (0.5 mM)
plotted against the statistical significance for all parasite proteins detected in this study. Proteins with a significant response and N-terminal glycine
(MG) are highlighted in green, those without MG highlighted in black. (E) Dose response to NMTi plotted for selected proteins with significant YnMyr
enrichment. (F) Dose response to NMTi plotted for selected SAG proteins assigned previously as base sensitive. See also Figure 3—figure
supplement 1 and Supplementary file 3.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Chemical inhibition of TgNMT.
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30% of our substrates were previously reported to be palmitoylated (Caballero et al., 2016;
Foe et al., 2015) and Supplementary file 4). Since palmitoylation is frequently enriched at the pro-
tein N-terminus, in close proximity to the myristate, we analysed the first 20 amino acid sequences
of our substrates (Figure 4—figure supplement 1A) and found that approximately half possessed
cysteine residues (sites of palmitoylation) and, hence, the potential for double acylation. This number
correlated well with the 54% palmitoylation prediction (Ren et al., 2008) for our substrate pool
(Supplementary file 4). The reported and predicted palmitoylation data suggested that 12 of the 18
PM substrates likely utilise double acylation for stable membrane attachment while the remaining six
may be targeted to the PM via alternative mechanisms. Of the 9 IMC localised substrates, 8 are
reported or predicted as palmitoylated as well as 4 of the 5 Golgi-localised ones. This indicates that
double acylation is a strong predictor for membrane targeting, albeit to different localisations within
the cell, suggesting that further signals are required for their definitive subcellular localisation.
Although the absence of palmitoylation cannot exclude the presence of other secondary signals,
such as polybasic regions and PPI sites, which could still aid in PM attachment, we predict that about
half of the substrates we identified are likely only myristoylated at the N-terminus. Consistent with
this, all cytosolic and proteasome localised substrates were deprived of any palmitoylation and only
3 of the 12 nuclear proteins were shown to be palmitoylated. Within this varied group were CDPK1
(Ojo et al., 2010; Pomel et al., 2008), the two phosphatases PPM2A and PPM2B (Yang et al.,
2019) and, surprisingly, the microneme protein MIC7 (Meissner et al., 2002). For these proteins
myristoylation is likely to serve a distinct function beyond just a simple PM anchor.
The availability of the myristoylated proteomes of Toxoplasma and the related P. falciparum
(Wright et al., 2014) allowed us to investigate conserved and non-conserved features of myristoyla-
tion across the Apicomplexa. First, we compared both myristoylated proteomes by converting Plas-
modium myristoylated proteins into Toxoplasma orthologues using EuPathDB (Aurrecoechea et al.,
2017) and compared the overlap of both species. This yielded 24 shared substrates, which corre-
sponds to 37% of the Toxoplasma and 63% of the P. falciparum experimentally validated myristoy-
lated proteome (Figure 4—figure supplement 1B). 39 substrates from the Toxoplasma dataset
have orthologues in P. falciparum and 30 of them contain the MG motif, hinting towards potentially
Figure 4. The myristoylated proteome of Toxoplasma gondii. (A) Distribution of the subcellular localisation across our substrate list. Analysis performed
using ToxoDB and the build in LOPIT predictor. (B) Substrate orthology within selected Apicomplexans. Analysis was performed using EuPathDB. See
also Figure 4—figure supplement 1 and Supplementary file 4.
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. The myristoylated proteome of Toxoplasma gondii.
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unexplored PfNMT substrates (Supplementary file 4). We also investigated substrate orthology
with other Apicomplexans (Figure 4B, Supplementary file 4). This analysis showed that the lowest
level of substrate conservation is present in Babesia and Cryptosporidium (28 orthologues), followed
by Plasmodium (39), Cyclospora (62), Eimeria and Neospora (69) and finally Hammondia (72). Prob-
ing these species-specific orthologues for the presence of the MG motif indicates that between 14
(Babesia) and 66 (Hammondia) proteins could be potential substrates of NMT (Figure 4B,
Supplementary file 4) and therefore could also be myristoylated in these species. 13 proteins,
including CDPK3, PKG, PKAr and ARO, were present in all analysed species, suggesting that their
myristoylation may be essential across the phylum (Supplementary file 4).
MIC7 is myristoylated and is important for Toxoplasma fitness in vitro
Within our substrate list three proteins were classified as micronemal by LOPIT prediction
(Figure 4A). TGGT1_249970 was recently described as a protein on the microneme surface where
dual acylation is important for its anchoring into the membrane (Bullen et al., 2016). The second
protein (TGGT1_309990) is annotated as a multi-pass transmembrane protein of unknown function.
The third, and perhaps the most interesting, was the microneme protein MIC7 (TGGT1_261780).
MIC7 has been reported to be a putative type I transmembrane protein, comprising an N-terminal
signal peptide, five EGF-like domains, a membrane-spanning region, and a short cytoplasmic tail
(Meissner et al., 2002). As MIC signal peptides are typically co-translationally cleaved upon entry
into the ER (Soldati et al., 2001), the presence of a myristate within the classical signal sequence of
MIC7 was unusual. In addition, MIC7 has been suggested to be predominantly expressed in brady-
zoites (Meissner et al., 2002), the lifecycle stage responsible for the chronic phase of T. gondii infec-
tion. As our experiments were performed exclusively in tachyzoites, the stage responsible for acute
infection, the presence of MIC7 within our dataset could represent a potential false positive identifi-
cation. To exclude this possibility, we mined MS-based quantification data from an experiment com-
paring bradyzoite and tachyzoite proteomes (Young et al., 2020; PXD019729). The log2 fold
changes in protein abundance for MIC7 and the bradyzoite-specific marker MAG1 (Tu et al., 2019;
Figure 5A, Supplementary file 5) revealed that in contrast to MAG1, MIC7 is expressed in tachy-
zoites, supporting the MS and transcriptional evidence in ToxoDB. We next aimed to directly vali-
date protein myristoylation using ectopically expressed HA-tagged MIC7 WT and myristoylation
mutant (Mut, G2G3 > KA) under control of either the endogenous or the strong tubulin promoter.
We metabolically labelled parasites with YnMyr and performed a myristoylation-dependent pull
down on lysates. Only WT but not the Mut was enriched in this manner (Figure 5B), confirming that
MIC7 is indeed myristoylated.
To investigate the functional relevance of MIC7 and its myristoylation, we created an inducible
knock-out (iKO) line using the DiCre/loxP system (Andenmatten et al., 2013) that we recently opti-
mised in RHDku80 parasites (Hunt et al., 2019). The Mic7 coding sequence was replaced with a
floxed, HA-tagged copy of the gene, hereafter called MIC7HA, that could be excised upon rapamy-
cin (RAPA) treatment (Figure 5C). We verified correct integration at the endogenous locus and con-
firmed RAPA-induced excision by PCR (Figure 5—figure supplement 1). At the protein level,
MIC7HA was efficiently depleted 24 hr post RAPA treatment (Figure 5D). Correct trafficking of
MIC7HA to micronemes was verified by the co-localisation with the micronemal marker MIC2
(Figure 5E). Upon deletion of Mic7, parasites no longer formed detectable plaques in host cell
monolayers after 5 days in culture, but we could observe very small plaques emerging after 7 days
(Figure 5F). Collectively these results demonstrate an important, but non-essential, role for MIC7 in
the lytic cycle.
Myristoylation of MIC7 appears important for host cell invasion
To investigate where in the lytic cycle MIC7 plays a role, and test the functional relevance of N-termi-
nal myristoylation, we complemented the iKO line by introducing Ty1-tagged WT or myristoylation
defective mutant (hereafter called cWT and cMut, respectively) copies of Mic7 into the Uprt locus
(Figure 6A). Both inserts were correctly integrated and both complemented lines retained efficient
RAPA-induced Mic7 excision (Figure 6—figure supplement 1) and depletion of MIC7HA
(Figure 6B). After confirming equivalent and RAPA-insensitive expression of cWT and cMut
(Figure 6B), we validated both lines in terms of their myristoylation-dependent enrichment and
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Figure 5. MIC7 is myristoylated and is important for T. gondii lytic cycle. (A) MS-based quantification of MIC7 and MAG1 abundance in tachyzoites [T]
and bradyzoites [B] of T. gondii. Significance calculated using two-tailed Student’s t-test, ***p=0.0002, N = 3, error bars represent standard deviation.
(B) MIC7 is myristoylated as shown by YnMyr-dependent pull down and western blotting with a-HA antibody. CDPK1 and SFP1 (TGGT1_289540) are
used as enrichment and loading controls, respectively. (C) Schematic representation of the DiCre/loxP-based iKO strategy used for the conditional
depletion of Mic7. Red hexagon represents STOP codon, rec - recodonized. (D) Validation of RAPA-dependent depletion of MIC7HA in the iKO line
illustrated by western blotting with a-HA antibody. Gra29 was used as loading control. (E) Co-localisation of MIC7HA (green) with the micronemal
marker MIC2 (red) in the iKO line by immunofluorescence analysis. Scale bar: 3 mm. (F) Plaque assays illustrating that MIC7 is important, but not
essential for the intracellular growth of Toxoplasma. Assay was performed for 5 days (where not indicated) in three biological replicates, each in
technical triplicate, representative images are shown. See also Figure 5—figure supplement 1.
Figure 5 continued on next page
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showed that only the cWT was selectively pulled down after metabolic labelling with YnMyr
(Figure 6C). In the next step, we investigated the co-localisation of MIC7HA with cWT and cMut
(Figure 6D). Both complementation isoforms localised to the micronemes, indicating that the myris-
tate is not required for the trafficking of MIC7 to this organelle.
We next sought to evaluate the role of MIC7 myristoylation in the parasite lytic cycle. While cWT
rescued the iKO phenotype upon RAPA treatment, cMut parasites formed substantially smaller pla-
ques under equivalent conditions (Figure 6E). This demonstrates that myristoylation indeed plays a
key role in MIC7 function. Given the well-established role of microneme proteins in facilitating host
cell penetration, we explored whether myristoylation of MIC7 may be important for invasion. We
treated iKO, cWT and cMut parasites with RAPA and performed a red/green assay (Huynh et al.,
2003) which can distinguish invaded from attached parasites. As shown in Figure 6F, we observed
efficient invasion of host cells by the cWT parasites. This was not the case in the iKO and cMut lines,
where invasion was reduced by 57% and 32%, respectively. Compared to the cWT line, we also
observed a consistent 61% drop in the total number of iKO parasites (Figure 6G), which suggests a
defect in the attachment to host cells. A modest but non-significant reduction of 15% in attachment
was observed in the cMut strain. Collectively, these results indicate that MIC7 plays an important
role in Toxoplasma propagation by facilitating parasite attachment and subsequent entry into host
cells. Furthermore, myristoylation is not required for sorting MIC7 to the micronemes but appears to
be important for its function in invasion of host cells.
Generation of double tagged MIC7 lines for in depth characterisation
of MIC7 myristoylation
To monitor MIC7 N-terminus, and thus the fate of the myristate, we generated double tagged MIC7
variants bearing a Myc tag in the ectodomain and a Ty1 tag at the C-terminus. Placing a Myc tag in
the region between the MIC7 transmembrane (TM) domain and the last predicted EGF domain
(EGF5) yielded non-functional protein (Figure 7—figure supplement 1A). To select a likely suitable
position for the tag, we resorted to structural predictions. The region between EGF5 and the TM
domain (EGF5-TM, residues 230–284) possesses two pairs of cysteine residues and may represent
either an extension of EGF5, or a non-canonical/truncated EGF6. This could explain the inability to
place an epitope tag in this region and yield functional MIC7. We also excluded EGF3 and EGF4,
that possess the strongest signatures for calcium-binding motifs (PFAM database domain entry
PF07645), which normally imparts a rigid domain arrangement with its neighbours. Finally, we con-
sidered possible locations (Figure 7A) where some degree of structural flexibility would be most
likely. The loop between the last two cysteine residues is variable amongst EGF domains, therefore
locations were chosen between C38 and C53 of EGF1 and between C86 and C97 of EGF2 as well as
within the linker between EGF1 and EGF2. Using ectopic expression, we tested all these positions in
terms of protein expression and localisation. All three double tagged protein variants localised to
micronemes (Figure 7—figure supplement 1B), but the most abundant protein levels were
observed when the Myc tag was placed within the EGF2 (Figure 7—figure supplement 1C). This
indicated that the tag is well tolerated in this position, readily detected by western blot and could
be used for further experiments. Myc tagged cWT and cMut (hereafter called MyccWT and MyccMut,
respectively) were then inserted into the Uprt locus of the iKO line. Both inserts correctly integrated,
the new lines retained efficient RAPA-induced Mic7 excision and depletion of MIC7HA (Figure 7—
figure supplement 1D–F). After verifying equivalent and RAPA independent expression of the
MyccWT and MyccMut (Figure 7—figure supplement 1F), we confirmed their micronemal localisation
by IFA (Figure 7—figure supplement 1G). Several microneme proteins have been shown to dimer-
ise (Cérède et al., 2002), which harbours the potential that any additional copy of a protein in a
merodiploid strain, even when lacking trafficking information, could piggy back as a heterodimer
into the micronemes. Indeed, when testing co-IPs in the absence of RAPA, we observed that both
Figure 5 continued
The online version of this article includes the following source data and figure supplement(s) for figure 5:
Source data 1. Numerical data of the graph presented in Figure 5A.
Figure supplement 1. Inducible knock-out of MIC7.
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Figure 6. Myristoylation of MIC7 plays a role in the invasion of host cells. (A) Complementation strategy used to evaluate the functional importance of
MIC7 myristoylation. The orientation of cWT and cMut is reversed in the Uprt locus with the Ty1 tag at the C-terminus. Red hexagon represents STOP
codon, rec – recodonized. (B) Western blot analysis demonstrating the RAPA-dependent depletion of MIC7HA in the iKO, cWT and cMut lines (a-HA) as
well as equivalent and RAPA-independent expression of the complements (a-Ty1). Gra29 was used as loading control. (C) Biochemical validation of
complemented lines by YnMyr-dependent pull down. Enrichment of WT and Mut copy of MIC7 was evaluated by western blotting with a-Ty1 antibody.
MIC7HA (a-HA) and Gra29 were used as enrichment and loading controls, respectively. (D) Co-localisation of MIC7HA (red) with the cWT and cMut
(green) by immunofluorescence analysis. Scale bar: 5 mm. (E) Plaque assay demonstrating that myristoylation of MIC7 is important in the intracellular
Figure 6 continued on next page
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complements can co-IP with MIC7HA (Figure 7B), which is independent of the myristate. We there-
fore repeated the localisation experiments in the presence of RAPA to delete MIC7HA. As shown in
Figure 7—figure supplement 1H, both MyccWT and MyccMut localise to the micronemes in RAPA-
treated parasites, confirming that the myristate is not necessary for MIC7 sorting.
Plaque assays of RAPA-treated complementation lines showed the expected defect in plaque for-
mation for MyccMut, however, we also observed a small reduction of plaque size for MyccWT express-
ing parasites as compared to the DMSO control (Figure 7C). This slightly reduced ability to form
plaques is likely due to the effect of Myc tag insertion on the MIC7 function. However, since the tag
is present in both complemented lines and the ability to form plaques was substantially more
impeded in the MyccMut parasites, these lines are still suitable to investigate the specific function of
MIC7 myristoylation.
MIC7 and its myristoylation are important for the initiation of host cell
invasion
In order to shed some light on MIC7 topology within the micronemes as well as the fate of its N-ter-
minal myristate, we performed proteinase K protection assays (Figure 7D). In these experiments,
proteins/domains that are accessible to proteinase K after digitonin-mediated plasma membrane
permeabilisation are digested, while those retained within organelles, such as the micronemes, are
protected from this proteolytic digest. We treated tachyzoites from both MyccWT and MyccMut lines
with RAPA to deplete MIC7HA and fed with YnMyr to allow for myristoylation-dependent pull down
of the complements. We then subjected parasites to digitonin and proteinase K treatment, followed
by detection of Myc and Ty1 tags. As a control we used antibodies against the ectodomain of MIC2,
as it should be protected (Bullen et al., 2016). Under these conditions the MIC7 C-terminus was
digested, while the N-terminus was protected as visualised by the Ty1 and the Myc antibodies,
respectively. As the parasites were treated with YnMyr prior to the experiment, we could use a
YnMyr-dependent pull down to demonstrate that the protected N-terminus of MIC7 remains myris-
toylated (Figure 7D). These results strongly suggest that MIC7 is indeed a transmembrane protein
with a myristoylated N-terminus facing the microneme lumen and a short C-terminal cytoplasmic tail
that faces the parasite cytoplasm.
Having established the presence of MIC7 N-terminal myristoylation within the micronemes, we
aimed to perform a more detailed characterisation of its function. First, we repeated invasion assays
in large scale as described in Touquet et al., 2018. We performed three independent experiments
with a total of 15 replicates per tested parasite line (Figure 7E). Taking into account the phenotypic
effect for the Myc tag insertion in complemented parasite lines we used untreated iKO parasites as
a parental control. Parasites that no longer expressed MIC7HA displayed a 78% decrease in invasive-
ness when compared to the control. Complementation with MyccWT copy can restore the invasive-
ness to 61%, while MyccMut reach only 30% invasion capacity. These results are largely consistent
with our previous observations (Figure 6F) and further confirm the critical role for MIC7 and its myr-
istoylation in the invasion process.
To gain a better understanding of the function of MIC7 during host cell penetration, we filmed
invasion of the DMSO and RAPA-treated iKO and the complemented lines into GFP-GPI expressing
host cells (Figure 7—videos 1–4). We calculated times of successful and failed invasions for each
genetic background and observed that despite different success rates between lines, the parasites
that did enter the host cell proceed with a similar speed as the control (Figure 7F, Figure 7—videos
Figure 6 continued
growth of Toxoplasma. Assay performed for 5 days in three biological replicates, each in technical triplicate, representative images are shown. (F)
Quantification of invasion efficiency in the RAPA-treated cWT, iKO and cMut lines. Figure shows the average of three biological replicates, each in
technical duplicate, error bars represent standard deviation. Significance calculated using 1-way ANOVA with Dunnett’s multiple comparison test,
**p=0.001, *p=0.018. (G) Quantification of attachment efficiency in the RAPA-treated cWT, iKO and cMut lines. Figure shows the average of three
biological replicates, each in technical duplicate, error bars represent standard deviation. Significance calculated using 1-way ANOVA with Dunnett’s
multiple comparison test, **p=0.004, ns = not significant. See also Figure 6—figure supplement 1.
The online version of this article includes the following source data and figure supplement(s) for figure 6:
Source data 1. Numerical data of the graphs presented in Figure 6F and G.
Figure supplement 1. Complementation of the MIC7 iKO line.
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Figure 7. Functional analysis of MIC7 and its myristoylation in double tagged MIC7 lines. (A) Schematic representation of MIC7 domain structure with
evaluated Myc tag positions indicated by arrows. (B) Western blot analysis showing co-immunoprecipitation of MyccWT and MyccMut (a-Myc) with
MIC7HA (a-HA). MIC2 and Gra29 were used as controls for microneme solubilisation and equal loading, respectively; In = input,
IP = immunoprecipitate, S = supernatant after IP. (C) Plaque assay confirming that myristoylation of MIC7 is important in the intracellular growth of
Figure 7 continued on next page
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1–4). This suggests a potential failure to initiate invasion. In several failed invasion events we also
observed a notable membrane invagination (Figure 7—figure supplement 2A, Figure 7—videos 2
and 4), which normally occurs after secretion of the rhoptry neck components required for the for-
mation of the tachyzoite-host cell junction (Bichet et al., 2016). It is worth noting, that the immuno-
fluorescent analysis of likely aborted invasion events in the RAPA treated iKO line revealed more
than half of extracellular parasites (45 of 68) show a strong arch-shaped morphology while associ-
ated with a host cell (Figure 7G). This is indicative of MIC7 KO parasites exerting force during the
attempt to invade, possibly leading to the zoite deformation.
The inability to initiate invasion in the iKO and MyccMut lines could be caused by a general defect
in gliding motility or a failure to secrete micronemes. However, both circular and helical trails were
detected with no obvious differences between parasites (Figure 7—videos 1–4, Figure 7—figure
supplement 2B). We also observed no reduction in microneme secretion, as shown by efficient
MIC2 processing in MIC7 KO parasites, even in the presence of 5-benzyl-3-isopropyl-1H-pyrazolo
[4,3-d]pyrimidin-7(6H)-one (BIPPO), a phosphodiesterase inhibitor that triggers signalling pathways
leading to increased parasite motility and microneme secretion (Figure 7—figure supplement 2C).
To get a better understanding of MIC7 distribution in parasites before and during invasion, we
co-localised MIC7 with SAG1, a well characterized surface marker, which can be used to delineate
the intra- and extracellular part of invading parasites. This revealed that MIC7 partially redistributes
around the periphery of extracellular and invading parasites, but appears absent from the tachy-
zoite-host cell junction (Figure 7H), a constriction through which the parasite moves as it enters the
host cell (Pavlou et al., 2018; Tyler et al., 2011). This redistribution suggests, but is not proof, that
MIC7, as many other microneme proteins, is secreted onto the parasite surface during or after
egress from the host cell. Most transmembrane microneme proteins undergo proteolytic maturation
Figure 7 continued
Toxoplasma in the newly generated lines. Assay performed for 5 days in three biological replicates, each in technical triplicate, representative images
are shown. (D) Proteinase K protection assay demonstrating that the N-terminus of MIC7 is myristoylated and protected (a-Myc) while the C-terminus is
digested (a-Ty1) upon permeabilisation and protease treatment. MIC2 was used as a known control where the ectodomain is protected under similar
conditions. Dig. = digitonin, Prot.K = proteinase K. (E) Quantitative large scale invasion assay. Results show the relative invasion rate as
mean ± standard deviation calculated from three independent assays, each performed with five replicates. The total number of intracellular tachyzoites
and human cells are indicated in each column. Two-tailed Student’s t-test was performed for two-group comparisons, ***p<0.0006, **p=0.0044. (F)
Distribution of the successful/failed invasion times for each of the four genetic backgrounds. Mean invasion time is displayed for both HFF and U2OS
host cells. (G) Representative immunofluorescence images (n = 45/68) demonstrating the characteristic bending of the conoid in extracellular RAPA-
treated iKO parasites stained against the surface protein SAG1 (marking extracellular parasites and the extracellular part of invading tachyzoites only). It
is also possible to observe the U2OS GFP-GPI membrane invagination at the vicinity of the extracellular parasites (white arrowheads). Scale bar: 5 mm.
(H) Representative immunofluorescence images of untreated (-RAPA) iKO parasites while extracellular (n = 63) and during invasion (n = 22). Parasites
were stained against SAG1 (marking extracellular parasites and the extracellular part of invading tachyzoites only) and a-HA to stain MIC7. Scale bar: 5
mm. (I) Analysis of MIC7 secretion upon stimulation with BIPPO. No shedding of MIC7 was observed (a-Myc) in contrast to MIC2 which was used as a
control. P - pellet, S - supernatant containing the excreted secreted antigens, M – molecular weight marker. White space was used to indicate where
gel lanes were not contiguous. (J) Immunofluorescence based quantification of pSTAT6 as a reporter for ROP16 secretion in all tested lines with and w/
o RAPA treatment. Figure shows the average of three biological replicates, error bars represent standard deviation. Significance calculated using 2-way
ANOVA with Sidak’s multiple comparison test, ***p=0.0004, **p=0.0013, ns = not significant. See also Figure 7—figure supplements 1 and 2.
The online version of this article includes the following video, source data, and figure supplement(s) for figure 7:
Source data 1. Numerical data of the graph presented in Figure 7E.
Source data 2. Numerical data of the graph presented in Figure 7F.
Source data 3. Numerical data of the graph presented in Figure 7J.
Figure supplement 1. Generation of doubly-tagged MIC7 lines.
Figure supplement 2. Functional analysis of MIC7 and its myristoylation.
Figure 7—video 1. Related to Figure 7F.
https://elifesciences.org/articles/57861#fig7video1
Figure 7—video 2. Related to Figure 7F.
https://elifesciences.org/articles/57861#fig7video2
Figure 7—video 3. Related to Figure 7F.
https://elifesciences.org/articles/57861#fig7video3
Figure 7—video 4. Related to Figure 7F.
https://elifesciences.org/articles/57861#fig7video4
Broncel et al. eLife 2020;9:e57861. DOI: https://doi.org/10.7554/eLife.57861 17 of 38
Research article Microbiology and Infectious Disease
near or within the transmembrane domain after egress and during invasion (Soldati et al., 2001).
This process is facilitated by subtilisin or rhomboid proteases and is thought to relieve the high affin-
ity interactions between the parasite and host cell receptors (Carruthers, 2006; Dowse and Soldati,
2005). We analysed if MIC7 could undergo similar processing and found that while MIC2 was effi-
ciently cleaved and released into the culture supernatant, this was not the case for MIC7, even in the
presence of BIPPO (Figure 7I). We also tested whether MIC7 could be shed during invasion by ana-
lysing the culture supernatant as well as parasite and host material of freshly invaded cells. Again, no
MIC7 shedding was observed (Figure 7—figure supplement 2D). These results are in agreement
with previously reported observations (Meissner et al., 2002), and confirm that MIC7 is not subject
to a proteolytic cleavage.
MIC7 and its myristoylation may be important for efficient secretion of
rhoptry contents into the host cell
The live imaging data of the iKO parasites suggested that MIC7 plays an important role in the onset
of invasion, potentially after the establishment of the tachyzoite-host cell junction. In one instance
we could observe a membrane swirl formation at the apex of the parasite attempting invasion, sug-
gesting that rhoptry contents may have been secreted (Figure 7—video 2). Rhoptries are apical
organelles which contain a number of kinases the parasite injects into the host cell upon invasion.
These effector kinases modulate many important functions in host-microbe interaction
(Boothroyd and Dubremetz, 2008). One of these kinases, the rhoptry kinase 16 (ROP16) acts as a
JAK mimetic leading to rapid and direct phosphorylation of STAT6 (Ong et al., 2010; Saeij et al.,
2007). Accordingly, we used STAT6 phosphorylation as a reporter for efficient rhoptry secretion and
ROP16 translocation into the host cell (Figure 7J). RAPA-treated MyccWT parasites showed 45%
pSTAT6 positive nuclei. RAPA-treated iKO and MyccMut parasites showed a significant reduction of
pSTAT6 positive nuclei (11% and 21%, respectively). No significant differences in pSTAT6 positive
cells between tested parasite lines were observed when treated with DMSO. This indicates that iKO
and MyccMut parasites can still secrete ROP16 into the host cell and induce STAT6 phosphorylation,
although at significantly reduced levels.
Discussion
Our understanding of myristoylation and its functional consequences in Toxoplasma is hampered by
the limited knowledge of NMT substrates. Using an integrated MS-approach we describe here the
first experimentally validated myristoylated proteome in T. gondii. We combine two orthogonal che-
moproteomic techniques, that is quantitative response to NMT inhibition with direct MS/MS evi-
dence for substrate modification, which allows for high confidence in substrate identification as well
as substantial substrate coverage. Despite the complex nature of our samples, consisting of both
human and parasite proteins, our discovery includes all proteins previously reported to be myristoy-
lated in Toxoplasma as well as novel and unexpected TgNMT substrates. The fact that these pro-
teins are functionally diverse, and involved in all steps of the lytic cycle highlights the importance of
myristoylation in Toxoplasma biology. Consistent with this, treatment with NMTi resulted in dose
dependent parasite killing. Although we cannot exclude small off-target effects of IMP-1002 that
was originally designed for Plasmodium spp., we predict that this severe phenotype was largely due
to pleiotropic effects of TgNMT inhibition on the Toxoplasma lytic cycle. Potent and selective
TgNMT inhibitors are yet to be reported, however extensive work in other protozoan parasites
(Ritzefeld et al., 2018) demonstrates that selective NMT inhibition could provide an attractive strat-
egy to combat infection. Moreover, results presented here indicate that related parasites, with high
structural conservation of their NMTs, could be inhibited by a single compound, which may allow for
the development of a pan-parasite inhibitor in the future.
Our substrates showed heterogeneous localisation with ca. 50% localised to PM or membrane
bound compartments. Palmitoylation analysis confirmed that for the majority of these substrates sta-
ble attachment to membranes is likely driven by double acylation. Although we cannot exclude the
presence of other secondary signals which could aid in PM targeting within our substrate pool, such
as polybasic regions and PPI sites, our analysis and the predicted localisation suggest that many of
our substrates may be myristoylated only, indicating that their myristoylation can serve more discrete
functions than just a priming site for the palmitate. Such alternate functions could include reversible
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membrane binding by the conformation regulated exposure of the myristate as shown for mamma-
lian ARF1 (Goldberg, 1998), regulation of protein activity as demonstrated for GPAT4 during glycer-
olipid synthesis (Zhu et al., 2019), or involvement in PPIs, as shown for the viral capsid assembly
(Chow et al., 1987; Mousnier et al., 2018).
Here we identified unexpected myristoylation of the Toxoplasma microneme protein 7 (MIC7).
Microneme proteins are key factors in Toxoplasma propagation involved in parasite egress, motility
and host cell invasion. They are trafficked into the secretory pathway by virtue of an N-terminal sig-
nal peptide that is cleaved during ER import (Soldati et al., 2001). We show that MIC7 is an impor-
tant, yet not essential protein and we unequivocally demonstrate that MIC7 is myristoylated at its
N-terminus, excluding the existence of an N-terminal signal sequence. While it is known that proteins
can enter the secretory pathway by virtue of a recessed signal or leader peptide, this has not been
reported for microneme proteins. Furthermore, many known microneme proteins are type I trans-
membrane proteins, where an N-terminal PPI or carbohydrate binding domain faces the microneme
lumen and a short cytoplasmic domain faces the parasite cytosol. Upon microneme secretion the
protein is transferred to the parasite PM, with the interacting domain exposed to bind to host cell
receptors. Because MIC7 lacks a signal peptide but otherwise mimics this domain structure, it most
likely enters the secretory pathway as a type III transmembrane protein (Goder and Spiess, 2001).
Although we have not specifically tested this here, this is supported by several features in the MIC7
primary amino acid sequence. That is: a transmembrane domain of > 20 amino acids in length (22 in
MIC7) and positive charges on the C-terminal side of the transmembrane domain.
We demonstrated that MIC7 and its myristoylation are important in host cell invasion. Live imag-
ing of the invasion process further revealed a potential defect in initiating invasion in the MIC7 KO
and myristoylation defective parasites. This phenomenon was not caused by a fault in microneme
secretion itself or parasite gliding. The live video analysis suggests that the parasites may be able to
initiate the tachyzoite-host cell junction (supported by some rhoptry content secretion as measured
by STAT6 phosphorylation), but then fail to progress beyond the initiation. This phenotype is similar
to Toxoplasma Myosin A knockout parasites, that are also able to initiate invasion, but then fail to
invade given the lack of a functional actin-myosin system. However, the strong arch-shaped deforma-
tion of extracellular MIC7 KO parasites in live invasion assays is substantially different from the
MyoA knockouts (Bichet et al., 2016). While we could not unequivocally show that MIC7 is secreted
to the zoite surface to engage with host cell receptors via its EGF domains, the fact that it redistrib-
utes around the periphery of the cell shortly after egress and during invasion supports this scenario.
When secreted, the myristate could contribute to specific PPIs with other surface proteins or poten-
tially host ligands to support attachment and initiate invasion.
It is also tempting to speculate that alternatively, the myristate could be inserted into the lipid
bilayer of the host cell. It has been shown that HBV viruses can utilise a myristoylated protein on
their surface to enter host cells (Maurer-Stroh and Eisenhaber, 2004). In Toxoplasma this mecha-
nism could contribute to host cell attachment, for which we observed a measurable defect upon
MIC7 deletion, but also to the earliest events of invasion, that is rhoptry secretion or host-cell pene-
tration. This is reminiscent of MIC8, another microneme protein, that has been implicated in a signal-
ling cascade leading to rhoptry discharge (Kessler et al., 2008). Our experiments to probe
secretion of ROP16, which rapidly phosphorylates STAT6 (Ong et al., 2010; Saeij et al., 2007), indi-
cate that rhoptry secretion per se is not affected upon MIC7 deletion, but reduced ROP16 mediated
STAT6 phosphorylation is observed. We cannot currently distinguish whether the decrease in ROP16
injected cells is due to decreased invasion efficiency of MIC7 KO and MyccMut lines, or whether
equal amounts of cells have been attempted to be invaded but ROP16 has not been efficiently trans-
ferred. However, the attachment phenotype observed for MIC7 myristoylation mutants is less pro-
found than the reduction of pSTAT6 induction, suggesting that the major cause of the rhoptry
secretion phenotype is independent of attachment and most likely due to an inefficient translocation
of rhoptry contents into the host cell. Whether the failure to progress beyond the initiation of the
tachyzoite-host cell junction lies in a failure to properly secrete rhoptry contents, or to form the junc-
tion itself remains to be clarified.
In summary we provide a useful resource of experimentally validated myristoylated and GPI-
anchored proteins, as well as first clues to the identity of so far uncharacterized myristoylated pro-
teomes across the phylum. We show that an NMT inhibitor that was generated against Plasmodium
spp. also inhibits Toxoplasma growth. The presence of several essential N-myristoylated proteins
Broncel et al. eLife 2020;9:e57861. DOI: https://doi.org/10.7554/eLife.57861 19 of 38
Research article Microbiology and Infectious Disease
conserved across many Apicomplexa indicates that NMT inhibition by a single compound may be a
viable strategy to target several pathogens. We have identified N-terminal myristoylation on a Toxo-
plasma protein that uses an unconventional mode of trafficking to the parasite secretory pathway
and the micronemes, and displays a novel use of myristoylation in parasite biology. This unexpected
discovery, which can likely be found in other organisms, demonstrates how our dataset can serve as
a tool in target-specific investigations that can ultimately help to unravel the exciting biology of
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Reagents: CuSO4, TCEP, TBTA, buffer salts, DTT, iodoacetamide, DMSO, BSA, Triton-X100 and
Tween-20 were from Sigma-Aldrich. Azide-PEG3-biotin was from Sigma-Aldrich. Peptide synthesis
coupling reagents HATU and HCTU were from Fluorochem and Merck, respectively. MS-grade
water, acetonitrile, methanol, TFA and formic acid were from Thermo Scientific. IMP-1002 was syn-
thesised as described in Schlott et al., 2019. BIPPO was synthesised as described in Howard et al.,
2015.
Plasmid generation
Primers used throughout this study are listed in Supplementary file 6. Plasmid sequences were con-
firmed by Sanger sequencing (Eurofins Genomics).
To generate the Mic7 iKO plasmid, pG140_MIC7_HA_iKO_loxP100, the Mic7 5’UTR with a loxP
site inserted 100 bp upstream of the Mic7 start codon, and a recodonised Mic7 cDNA-HA sequence,
were synthesized (GeneArt strings, Life Technologies). These DNA fragments were Gibson cloned
into the ApaI/PacI digested parental vector p5RT70loxPKillerRedloxPYFP-HX (Andenmatten et al.,
2013) to generate an intermediate plasmid. The Mic7 3’UTR was subsequently amplified from geno-
mic DNA using primers 1 and 2, while mCherry flanked by Gra gene UTRs was amplified from
pTKO2C (Caffaro et al., 2013) using primer pair 3/4. The resulting fragments were Gibson cloned
into the SacI-digested intermediate plasmid to generate pG140_MIC7_HA_iKO_loxP100.
To generate the complementation construct pUPRT_MIC7_Ty1, the Mic7 sequence flanked by its
5’UTR was amplified from genomic DNA using primer pair 5/6. In parallel, the Uprt targeting vector
pUPRT_HA (Reese et al., 2011) was amplified by inverse PCR using primers 7 and 8. The resulting
PCR amplicons were Gibson cloned to generate pUPRT_MIC7_Ty1. Primers 5 and 8 comprise over-
hangs to facilitate introduction of a Ty1 tag 3’ of the Mic7 sequence.
To generate the complementation construct pUPRT_MIC7(G2K/G3A)_Ty1, the Mic7 5’UTR and
Mic7 endogenous sequence were amplified using primer pairs 9/10 and 5/11, respectively. In paral-
lel, the Uprt targeting vector pUPRT_HA (Reese et al., 2011) was amplified by inverse PCR using
primers 7 and 8. The resulting PCR amplicons were Gibson cloned to generate pUPRT_MIC7(G2K/
G3A) _Ty1. Primers 9 and 11 comprise overhangs that introduce point mutations G2K and G3A,
while primers 5 and 8 introduce a Ty1 tag 3’ of the Mic7 sequence.
To generate the complementation construct pUPRT_Myc_MIC7_Ty1, the Myc tag coding
sequence was introduced within pUPRT_MIC7_Ty1 plasmid by inverse PCR using primers 12 and 13.
The resulting linear fragment was circularized using KLD reaction buffer (NEB) as per manufacturer’s
instructions.
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To generate the complementation construct pUPRT_Myc_MIC7(G2K/G3A)_Ty1, the Myc tag cod-
ing sequence was introduced within pUPRT_MIC7(G2K/G3A)_Ty1 plasmid by inverse PCR using pri-
mers 12 and 13. The resulting linear fragment was circularized using KLD reaction buffer (NEB) as
per manufacturer’s instructions.
To generate pSag1_Cas9-U6_sgMIC7, the pSag1_Cas9-U6_sgUPRT (Shen et al., 2014; Addgene
plasmid # 54467) vector was amplified by inverse PCR using primers 14 and 15. Primer 15 comprises
a sequence extension that replaces the Uprt-targeting sgRNA with a sgRNA sequence targeting
Mic7. The resulting linear fragment was circularized using KLD reaction buffer (NEB) as per manufac-
turer’s instructions.
To generate pGra_5’UTRMIC7_MIC7_HA, the 5’UTR of Mic7 was amplified from gDNA using
primer pair 30/31, and recodonised Mic7 sequence was amplified from pG140_MIC7_HA_iKO_-
loxP100 using primers 32 and 33. In parallel, the vector pGra_ApiAT5-3_HA (Wallbank et al., 2019)
was amplified by inverse PCR using primer pair 34/35. The three resulting PCR amplicons were Gib-
son assembled to generate pGra_5’UTRMIC7_MIC7_HA.
To generate pGra_5’UTRMIC7_MIC7(G2K/G3A)_HA, the 5’UTR of Mic7 was amplified from
gDNA using primer pair 30/31, and recodonised Mic7(G2K/G3A) sequence was amplified from
pG140_MIC7_HA_iKO_loxP100 using primers 36 and 33. Primer 36 was used to introduce the point
mutations G2K and G3A into the Mic7 recodonised sequence. In parallel, the vector pGra_ApiAT5-
3_HA (Wallbank et al., 2019) was amplified by inverse PCR using primer pair 34/35. The three
resulting PCR amplicons were Gibson assembled to generate pGra_5’UTRMIC7_MIC7(G2K/G3A)
_HA.
To generate pGra_5’UTRTUB_MIC7_HA, the Tub 5’UTR was amplified from gDNA using primer
pair 37/38, and recodonised Mic7 sequence was amplified from pG140_MIC7_HA_iKO_loxP100
using primers 39 and 33. In parallel, the vector pGra_ApiAT5-3_HA (Wallbank et al., 2019)
sequence was amplified by inverse PCR using primer pair 34/40. The three resulting PCR amplicons
were Gibson assembled to generate pGra_5’UTRTUB_MIC7 _HA.
To generate pGra_5’UTRTUB_MIC7(G2K/G3A)_HA, the Tub 5’UTR was amplified from gDNA
using primer pair 37/38, and recodonised Mic7(G2K/G3A) sequence was amplified from pG140_MI-
C7_HA_iKO_loxP100 using primers 41 and 33. Primer 41 was used to introduce the point mutations
G2K and G3A into the Mic7 recodonised sequence. In parallel, the vector pGra_ApiAT5-3_HA
(Wallbank et al., 2019) was amplified by inverse PCR using primer pair 34/40. The three resulting
PCR amplicons were Gibson assembled to generate pGra_5’UTRTUB_MIC7(G2K/G3A) _HA.
To generate pGra_5’UTRMIC7_Myc1_MIC7_HA, pGra_5’UTRMIC7_Myc1/2_MIC7_HA and
pGra_5’UTRMIC7_Myc2_MIC7_HA, the Myc tag coding sequence was introduced at different posi-
tions within pGra_5’UTRMIC7_MIC7_HA plasmid by inverse PCR using primers 42 and 43 (Myc1), 44
and 45 (Myc1/2), and 46 and 47 (Myc2). The resulting linear fragments were circularized using KLD
reaction buffer (NEB) as per manufacturer’s instructions.
Parasite line generation
Freshly harvested parasites were transfected by electroporation (1500 V) using the Gene Pulser Xcell
system (Bio-Rad) as previously described (Soldati and Boothroyd, 1993).
To generate the inducible MIC7 knock-out line (RH DiCreDku80Dhxgprt_loxPMIC7_HA, referred
to here as iKO MIC7), the plasmid pG140_MIC7_HA_iKO_loxP100 was linearized using PciI and co-
transfected with pSag1_Cas9-U6_sgMIC7 into the RH DiCreDku80Dhxgprt line (Hunt et al., 2019).
Recombinant parasites were selected 24 hr post transfection by addition of mycophenolic acid
(MPA; 25 mg/mL) and xanthine (XAN; 50 mg/mL) to culture medium. Resistant non-fluorescent para-
sites were cloned, and successful 5’ and 3’ integration at the Mic7 locus was confirmed using primer
pairs 16/17 and 18/19, respectively. Absence of the endogenous Mic7 locus was confirmed using pri-
mers 24 and 25. Rapamycin-induced excision of the loxPMic7 sequence was confirmed using primer
pair 26/27.
To complement the iKO MIC7 line with MIC7-expressing constructs, pUPRT_MIC7_Ty1 and
pUPRT_MIC7(G2K/G3A)_Ty1 or pUPRT_Myc_MIC7_Ty1 and pUPRT_Myc_MIC7(G2K/G3A)_Ty1 plas-
mids were linearized with ScaI and individually co-transfected with pSAG1_Cas9-U6_sgUPRT. Trans-
genic parasites were subjected to 5’-fluo-2’-deoxyuridine (FUDR) selection (5 mM) 24 hr post
transfection. Resistant parasites were cloned, and successful 5’ and 3’ integration was confirmed
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using primer pairs 20/21 and 22/23. Disruption of the endogenous Uprt locus was confirmed using
primer pair 28/29.
To generate lines that express WT and myristoylation mutant (G2K/G3A) MIC7 ectopically, plas-
mids pGra_5’UTRMIC7_MIC7_HA, pGra_5’UTRMIC7_MIC7(G2K/G3A)_HA, pGra_5’UTRTUB_MI-
C7_HA, and pGra_5’UTRTUB_MIC7(G2K/G3A)_HA were linearized using NotI and individually
transfected into the RH Dhxgprt strain. Recombinant parasites were selected 24 hr post transfection
by addition of mycophenolic acid (MPA; 25 mg/mL) and xanthine (XAN; 50 mg/mL) to culture
medium.
To generate lines that ectopically express MIC7 with Myc tag within the EGF1, EGF1/2 or EGF2
domains, plasmids pGra_5’UTRMIC7_Myc1_MIC7_HA, pGra_5’UTRMIC7_Myc1/2_MIC7_HA and
pGra_5’UTRMIC7_Myc2_MIC7_HA were linearized using NotI and individually transfected into the
RH Dhxgprt strain. Recombinant parasites were selected 24 hr post transfection by addition of myco-
phenolic acid (MPA; 25 mg/mL) and xanthine (XAN; 50 mg/mL) to culture medium.
Cell culture
Parasites of the RH strain were cultured in Human foreskin fibroblasts (HFFs) monolayers in Dulbec-
co’s Modified Eagle Medium (DMEM), GlutaMAX (Thermo Fisher) supplemented with 10% heat-inac-
tivated foetal bovine serum (FBS; Life technologies), at 37˚C and 5% CO2. All strains and host cell
lines tested negative for the presence of mycoplasma.
Metabolic labelling and cell lysis
Upon infection of HFF monolayers the medium was removed and replaced by fresh culture medium
supplemented with 25 mM YnMyr (Iris Biotech) or Myr (Tokyo Chemical Industry). The parasites were
then incubated for 16 hr, washed with PBS (2x) and lysed on ice using a lysis buffer (PBS, 0.1% SDS,
1% Triton X-100, EDTA-free complete protease inhibitor (Roche Diagnostics)). Lysates were kept on
ice for 20 min and centrifuged at 17,000  g for 20 min to remove insoluble material. Supernatants
were collected and protein concentration was determined using a BCA protein assay kit (Pierce).
Click reaction and pull down
Lysates were thawed on ice. Proteins (100–300 mg) were taken and diluted to 1 mg/mL using the
lysis buffer. A click mixture was prepared by adding reagents in the following order and by vortexing
between the addition of each reagent: a capture reagent (stock solution 10 mM in water, final con-
centration 0.1 mM), CuSO4 (stock solution 50 mM in water, final concentration 1 mM), TCEP (stock
solution 50 mM in water, final concentration 1 mM), TBTA (stock solution 10 mM in DMSO, final con-
centration 0.1 mM). Following the addition of the click mixture the samples were vortexed (room
temperature, 1 hr), and the reaction was stopped by addition of EDTA (final concentration 10 mM).
Subsequently, proteins were precipitated (chloroform/methanol, 0.25:1, relative to the sample vol-
ume), the precipitates isolated by centrifugation (17,000 x g, 10 min), washed with methanol (1 
400 mL) and air dried (10 min). The pellets were then resuspended (final concentration 1 mg/mL,
PBS, 0.4% SDS) and the precipitation step was repeated to remove excess of the capture reagent.
Next, samples were added to 15 mL of pre-washed (0.2% SDS in PBS (3  500 mL)) Dynabeads
MyOne Streptavidin C1 (Invitrogen) and gently vortexed for 90 min. The supernatant was removed
and the beads were washed with 0.2% SDS in PBS (3  500 mL).
SDS-PAGE, in gel fluorescence and western blotting
Beads were supplemented with 2% SDS in PBS (20 mL) and 4x SLB (Invitrogen), boiled (95˚C, 10
min), centrifuged (1000 x g, 2 min) and loaded on 10% or 4–20% SDS-PAGE gel (Bio-Rad). Following
electrophoresis (60 min, 160V), gels were washed with water (3x). In-gel fluorescence was detected
using a Pharos FX Plus Imager (Bio-Rad) and the protein loading was checked by Coomassie stain-
ing. For western blotting proteins were transferred (25 V, 1.3 A, 7 min) onto nitrocellulose mem-
branes (Bio-Rad) using Bio-Rad Trans Blot Turbo transfer system. After a brief wash with PBS-T (PBS,
0.1% Tween-20) membranes were blocked (5% milk, TBS-T, 1 hr) and incubated with primary anti-
bodies (5% milk, TBS-T, overnight, 4˚C) at the following dilutions: rat anti-HA (1:1000; Roche Diag-
nostics), mouse anti-Myc (1:1000; Millipore), mouse anti-Ty1 (1:2000; Thermo Fisher), rabbit anti-
Gra29 (1:1000; [Young et al., 2020]), rabbit anti-SFP1 (1:1000; [Young et al., 2020]), mouse anti-
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Toxoplasma (1:1000; Abcam), mouse anti-CDPK1 (1:3000; Matt Bogyo Lab), rabbit anti-SAG1
(1:10,000; John Boothroyd Lab), rabbit anti-GAP45 (1:1000; Peter Bradley Lab), rabbit anti-TgCAP
(1:2000; [Hunt et al., 2019]), rabbit anti-MIC2 (1:500; Vernon Carruthers Lab), and mouse anti-MIC2
(6D10) (1:1000; Vernon Carruthers Lab). Following washing (TBS-T, 3x) membranes were incubated
with IR dye-conjugated secondary antibodies from LI-COR Biosciences (1:10,000, 5% milk, TBS-T, 1
hr), and after a final washing step imaged on a LiCOR Odyssey imaging system (LI-COR Biosciences).
In case of a biotin western blot, membranes were blocked with 3% BSA and incubated with Strepta-
vidin-HRP (1:4000; Thermo Scientific) in 0.3% BSA, PBS-T for 1 hr. ECL western blotting Detection
Reagent (GE Healthcare) was then used for chemiluminescence based imaging on a ChemiDoc MP
Imaging System (Bio-Rad).
Synthesis of capture reagents
TEV reagent: Solid phase synthesis took place on a CF peptide synthesizer (Intavis) using a Rink
Amide LL resin (100 mmol; Merck) and N(a)-Fmoc amino acids, including Fmoc-Lys(N3)-OH (Fluoro-
chem) and Fmoc-Gly-(Dmb)Gly-OH (Merck). HCTU was used as the coupling reagent with 5-fold
excess of amino acids. Fmoc-Lys(Biotin)-OH (four eq; Merck) in 6 mL DMSO:NMP (1:1) was coupled
manually after automated assembly of the rest of the chain. DIPEA (four eq) was added, followed by
HOBt (1 M, four eq) in NMP. After 3 min DIC (four eq) was added, then after 30 min the solution
was added to the resin and allowed to react overnight. The resin was washed with DCM and DMF
prior to manual Fmoc removal and acetylation. The peptide was cleaved from the resin and protect-
ing groups removed by addition of a cleavage solution (95% TFA, 2.5% H2O, 2.5% TIS). After 2 hr,
the resin was removed by filtration and peptides were precipitated with diethyl ether on ice. The
peptide was isolated by centrifugation, then dissolved in H2O and freeze dried overnight. After dis-
solving in methanol, portions of the peptide were purified on a C8 reverse phase HPLC column (Agi-
lent PrepHT Zorbax 300 SB-C8, 21.2  250 mm, 7 m) using a linear solvent gradient of 13–50%
MeCN (0.08% TFA) in H2O (0.08% TFA) over 40 min at a flow rate of 8 mL/min. The peak fraction
was analysed by LC–MS on an Agilent 1100 LC-MSD. The calculated molecular weight of the peptide
was in agreement with the mass found. Calculated MW: 1804.08, actual mass: 1803.87.
Trypsin reagent: Solid phase synthesis took place on a CF peptide synthesizer (Intavis) using a
Fmoc-PEG-Biotin NovaTag resin (100 mmol; Merck), 2-Azidoacetic acid (Fluorochem) and N(a)-Fmoc
amino acids, including Fmoc-Lys(MMT)-OH (Merck). HATU was used as the coupling reagent with 5-
fold excess of amino acids. Following chain assembly, the MMT protecting group was removed from
the peptidyl-resin by treatment with 1% TFA in DCM (10 mL for 2 min x 8) and the resin washed with
DCM and DMF. Next 5-TAMRA (four eq; Anaspec) was dissolved in 1 mL DMSO:NMP (1:1). DIPEA
(four eq) was added, followed by HOBt (1 M, four eq) in NMP. After 3 min DIC (four eq) was added,
then after 30 min the solution was added to the resin and allowed to react overnight. After washing
the resin with DMF and DCM, the peptide was cleaved from the resin and protecting groups
removed by addition of a cleavage solution (95% TFA, 2.5% H2O, 2.5% TIS). After 2 hr, the resin was
removed by filtration and peptides were precipitated with diethyl ether on ice. The peptide was iso-
lated by centrifugation, then dissolved in H2O and freeze dried overnight. After dissolving in MeCN:
H2O (1:1), portions of the peptide were purified on a C8 reverse phase HPLC column (Agilent
PrepHT Zorbax 300 SB-C8, 21.2  250 mm, 7 m) using a linear solvent gradient of 10–50% MeCN
(0.08% TFA) in H2O (0.08% TFA) over 40 min at a flow rate of 8 mL/min. The peak fraction was ana-
lysed by LC–MS on an Agilent 1100 LC-MSD. The calculated molecular weight of the peptide was in
agreement with the mass found. Calculated MW: 1396.31, actual mass: 1395.60.
Sample preparation for MS-based proteomics
Click reaction - Reagent 1 and 2: lysates were thawed on ice and the click reaction was carried out
with 1 mg of proteins at 2 mg/mL. Proteins were captured by adding a mixture of respective capture
reagent (final concentration 0.1 mM), CuSO4 (final concentration 1 mM), TCEP (final concentration 1
mM) and TBTA (final concentration 0.1 mM). The samples were vortex-mixed (room temperature, 1
hr) before the addition of EDTA (final concentration 10 mM), methanol (four volumes), chloroform (1
vol), and water (three volumes). The samples were vortex-mixed briefly, centrifuged (10,000  g, 20
min) and the resulting pellets were either washed with methanol (four volumes) and dried (reagent
1) or resuspended (at 2 mg/mL, 1% SDS in PBS) after which the precipitation step was repeated and
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the resulting pellets washed with methanol (four volumes) and dried (reagent 2). Reagent 3: lysates
were thawed on ice and the click reaction was carried out with 1 mg of proteins at 2 mg/mL. Pro-
teins were captured by sequential addition of the capture reagent (final concentration 0.1 mM),
TCEP (final concentration 1 mM), TBTA (stock in DMSO:t-Butanol 1:4, final concentration 0.1 mM)
and CuSO4 (final concentration 1 mM) with mixing between each step. The samples were incubated
at room temperature for 1 hr before the addition of EDTA (final concentration 10 mM), methanol
(four volumes), chloroform (1 vol), and water (three volumes). The samples were vortex-mixed briefly,
centrifuged (10,000  g, 20 min) and the resulting pellets were washed with methanol (four volumes)
and dried. Subsequently, the dried pellets were resuspended in 2% SDS in PBS and, once
completely dissolved, PBS was added (final concentration 0.8% SDS, 2 mg/mL). For samples treated
with base, NaOH was added (final concentration 0.2 M, 1 hr) followed by neutralisation with equiva-
lent amount of HCl. Base-treated and untreated samples were then diluted (1 mg/mL, 0.4% SDS, 1
mM DTT) before pull down.
Pull down, reduction and alkylation - NeutrAvidin agarose resin (Thermo Scientific) was washed
with 0.2% SDS in PBS (3x). Typically, 50 mL of bead slurry was used for 1 mg of lysate. The samples
were added to beads and the enrichment was carried out with gentle mixing (2 hr, room tempera-
ture). Following the removal of supernatants, the beads were sequentially washed with 1% SDS in
PBS (3x), 4 M urea in PBS (2x) and 50 mM ammonium bicarbonate (3x). The samples were reduced
(5 mM DTT, 56˚C, 30 min) and cysteines alkylated (10 mM iodoacetamide, room temperature, 30
min) in the dark with washing the beads (2x, 50 mM ammonium bicarbonate) after each step.
Protein digestion - for samples processed with reagent 1 and 2 as well as for supernatants (pro-
teomes) MS grade trypsin (Promega) was used at 1:1000 w/w protease:protein, and samples were
incubated overnight at 37˚C. For reagent 3 two digestion strategies were used. TEV I: beads were
washed (2x) with water followed by TEV buffer (50 mM TrisHCl, 0.5 mM EDTA, 1 mM DTT, pH 8.0)
and the TEV protease (50 units; Invitrogen) was added. Samples were incubated overnight at 30˚C.
Supernatant was then removed and beads washed with TEV buffer (1x, 50 mL). The wash fraction
was combined with the supernatant and stored at 4˚C. A fresh portion of TEV protease (20 units)
was then added to beads which were incubated for additional 6 hr at 30˚C. The supernatant and
wash were combined with the first TEV elution. MS grade trypsin was subsequently added at 1:1000
w/w protease:protein, and samples were incubated overnight at 37˚C. TEV II: samples were incu-
bated overnight at 37˚C with MS grade trypsin at 1:1000 w/w protease:protein. The supernatant was
removed (fraction 1) and beads washed with water and TEV buffer (2x each). The TEV protease was
then added (50 units) and beads incubated overnight at 30˚C (fraction 2).
Stage tip - samples were desalted prior to LC-MS/MS using Empore C18 discs (3M). Each stage
tip was packed with one C18 disc, conditioned with 100 mL of 100% methanol, followed by 200 mL
of 1% TFA. The samples were loaded in 1% TFA, washed 3 times with 200 mL of 1% TFA and eluted
with 50 mL of 50% acetonitrile, 5% TFA. Desalted peptides were vacuum dried in preparation for LC-
MS/MS analysis.
Chemical inhibition of TgNMT
HFFs were infected with Toxoplasma and cultured for 16 hr. The medium was then replaced and
intracellular parasites co-treated with 25 mM YnMyr and the indicated concentrations of IMP-1002
for 5 hr. Following PBS wash (2x) the cells were lysed on ice using the lysis buffer and further proc-
essed exactly as described above. The click reaction, pull down on NeutrAvidin beads and the MS
sample prep were performed as described above for reagent 1 and 2.
LC-MS/MS
Samples were resuspended in 0.1% TFA and loaded on a 50 cm Easy Spray PepMap column (75 mm
inner diameter, 2 mm particle size, Thermo Fisher Scientific) equipped with an integrated electro-
spray emitter. Reverse phase chromatography was performed using the RSLC nano U3000 (Thermo
Fisher Scientific) with a binary buffer system (solvent A: 0.1% formic acid, 5% DMSO; solvent B: 80%
acetonitrile, 0.1% formic acid, 5% DMSO) at a flow rate of 250 nL/min. Samples processed with
reagent 1 were run on a linear gradient of 2–35% B in 90 min with a total run time of 120 min includ-
ing column conditioning. Samples processed with reagents 2 and 3 were run on a linear gradient of
2–40% B or 2–55% B (TEV II myristoylated peptide fraction) in 155 min with a total run time of 180
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min including column conditioning. The nanoLC was coupled to a Q Exactive mass spectrometer
using an EasySpray nano source (both Thermo Fisher Scientific). The Q Exactive was operated in
data-dependent mode, acquiring HCD MS/MS scans (R = 17,500) after an MS1 survey scan
(R = 70,000) on the 10 most abundant ions using MS1 target of 1E6 ions, and MS2 target of 5E4
ions. The maximum ion injection time utilised for MS2 scans was 120 ms, the HCD normalised colli-
sion energy was set at 28 and the dynamic exclusion was set at 30 s. The peptide match and isotope
exclusion functions were enabled. NMTi samples were run on a linear gradient of 2–20% B in 55 min,
followed by 20–40% B in 35 min and 40–60% B in 5 min with a total run time of 120 min including
column conditioning. The nanoLC was coupled to a Orbitrap Lumos mass spectrometer using an
EasySpray nano source (both Thermo Fisher Scientific). The Orbitrap Lumos was operated in data-
dependent mode (3 s cycle time), acquiring IT HCD MS/MS scans in rapid mode after an MS1 survey
scan (R = 120, 000). The MS1 target was 4E5 ions whereas the MS2 target was 2E3 ions. The maxi-
mum ion injection time utilised for MS2 scans was 300 ms, the HCD normalised collision energy was
set at 32 and the dynamic exclusion was set at 30 s.
Data analysis
Acquired raw files were processed with MaxQuant, versions 1.5.0.25 and 1.5.2.8 (Cox and Mann,
2008). Peptides were identified from the MS/MS spectra searched against Toxoplasma gondii (com-
bined TG1, ME49 and VEG proteomes, ToxoDB) and Homo sapiens (UniProt) proteomes using
Andromeda (Cox et al., 2011) search engine. Cysteine carbamidomethylation was selected as a
fixed modification and methionine oxidation was selected as a variable modification. The enzyme
specificity was set to trypsin with a maximum of 2 missed cleavages. The precursor mass tolerance
was set to 20 ppm for the first search (used for mass re-calibration) and to 4.5 ppm for the main
search. The datasets were filtered on posterior error probability (PEP) to achieve a 1% false discov-
ery rate on protein, peptide and site level. Other parameters were used as pre-set in the software.
‘Unique and razor peptides’ mode was selected to allow identification and quantification of proteins
in groups (razor peptides are uniquely assigned to protein groups and not to individual proteins).
Label-free quantification (LFQ) in MaxQuant was performed using a built-in label-free quantification
algorithm (Cox and Mann, 2008) enabling the ‘Match between runs’ option (time window 0.7 min)
within replicates. Each experiment comprised of replicates treated with YnMyr and the same number
of replicates treated with Myr control or NMTi. The LFQ is based on intensities of proteins calculated
by MaxQuant from peak intensities and based on the ion currents carried by peptides whose
sequences match a specific protein or a protein group to provide an approximation of abundance.
Myristoylated peptide search in MaxQuant was performed as described above applying the fol-
lowing variable modifications: cysteine carbamidomethylation, +463.2907 (reagent 2) and
+491.3220 (reagent 3) at any peptide N-terminus and cysteine residues. In addition, the minimum
peptide length was reduced to six amino acids and the ‘Match between runs’ option was disabled.
MaxQuant utilises a scoring algorithm when matching experimental MS/MS spectra with a library of
theoretical spectra generated from the in silico digestion of proteins within databases selected for
the search. The algorithm is used to evaluate the quality of peptide-spectrum matches (PSMs). To
each PSM, MaxQuant also attributes a delta score, which is a difference between scores associated
with the match to the best peptide candidate and the second best match within the database. The
higher the score and the delta score, the more reliable the identification. In order to reduce a possi-
bility for a false peptide sequence assignment even further, we applied relatively high delta score
thresholds (20 vs 6 pre-set as default) for all myristoylated peptides in our analysis. MaxQuant output
files were processed with Perseus, version 1.5.0.9 (Tyanova et al., 2016) as described in the Results
section and in Supplementary files 1–3. The mass spectrometry proteomics data have been depos-
ited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2019) partner reposi-
tory with the dataset identifier PXD019677.
Homology modelling of TgNMT onto PvNMT crystal structure
The model of TgNMT was generated using SWISS-MODEL (Waterhouse et al., 2018), and aligned
with a crystal structure of PvNMT bound to NMT inhibitor IMP-1002 (PDB: 6MB1). The structural
image was generated using PyMOL (Schrodinger LLC (2010), The PyMOL Molecular Graphics Sys-
tem, Version 1.3r1).
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MIC7 expression in tachyzoites and bradyzoites
HFF monolayers were infected with Pru Dhxgprt parasites in triplicate. For tachyzoite samples an
MOI of 1 was used for a 27 hr infection. For bradyzoite samples monolayers were infected at an MOI
of 0.8 for 3.5 hr, washed and grown in switch conditions (RPMI, 1% FBS, pH 8.1, ambient CO2) for 3
days. Triplicate samples were lysed in 2 mL ice cold lysis buffer (50 mM Tris-HCl, 75 mM NaCl, 8 M
urea, pH 8.2), supplemented with protease (Roche Diagnostics) and phosphatase (Phos Stop, Roche
Diagnostics) inhibitors. Lysis was followed by sonication to reduce sample viscosity (30% duty cycle,
3  30 s bursts, on ice). Protein concentration was measured using a BCA protein assay kit (Pierce).
Lysates (1 mg per condition) were subsequently processed for mass spectrometry as described
(Young et al., 2020) and data analysis performed as explained in Supplementary file 5. For full
dataset please see Young et al., 2020 and PXD019729.
Depletion of Mic7
Parasites were allowed to invade HFFs for 2 hr and then treated with 50 nM rapamycin (Sigma-
Aldrich) or an equivalent volume of vehicle (DMSO) for 4 hr. The medium was then replaced and the
parasites allowed to grow for at least 24 hr prior to PCR and western blot analysis.
Parasite preparation for large scale invasion assay/live microscopy/gliding:
HFF monolayers in T25 flasks were infected in culture conditions (37˚C and 5% CO2) with recently
egressed tachyzoites to achieve a one to two-per-cell parasite infection. Non-internalized parasites
were removed with PBS, and the infected monolayers were cultivated for about 2 hr in complete cul-
ture medium (DMEM supplemented with 10% FCS, 10 mM HEPES, 100 units/mL penicillin, and 100
mg/mL streptomycin). After 2 hr incubation the parasites were treated with 50 nM rapamycin or
vehicle. Following a 14 hr incubation the medium was replaced with the complete medium and
tachyzoites were used within 2 to 5 hr post-egress.
Plaque assays
Parasites were harvested by syringe lysis, counted, and 400 parasites were seeded on confluent HFF
monolayers grown in 24-well plates (Falcon). Parasites were allowed to invade overnight prior to
treatment with 50 nM rapamycin or vehicle (DMSO) for 4 hr. Following medium replacement to stan-
dard culture medium, plaques were allowed to form for 5 days. iKO MIC7 line: Parasites were har-
vested by syringe lysis, counted, and 100 parasites were seeded on confluent HFF monolayers
grown in 24-well plates (Falcon). Parasites were allowed to invade overnight prior to treatment with
50 nM rapamycin or vehicle (DMSO) for 4 hr. Following medium replacement to standard culture
medium, plaques were allowed to form for 7 days. NMTi: Parasites were harvested by syringe lysis,
counted, and 200 parasites were seeded on confluent HFF monolayers grown in the presence of
IMP-1002 for 5 days.
Plaque formation was assessed by inspecting the methanol fixed and 0.1% crystal violet stained
HFF monolayers.
Immunofluorescence analysis
Parasite-infected HFF monolayers grown on glass coverslips were fixed with 3% formaldehyde for 15
min prior to washing with PBS. Fixed cells were then permeabilised (0.2% Triton X-100/PBS, 10 min),
blocked (3% BSA/PBS, 1 hr) and stained for 1 hr with primary antibodies at the following dilutions:
rat anti-HA (1:1000; Roche), mouse anti-Myc (1:1000; Millipore), mouse anti-Ty1 (1:500; Thermo
Fisher), rabbit anti-MIC2 (1:5000; Vernon Carruthers Lab). Labelled proteins were visualised with
Alexa Fluor-conjugated secondary goat antibodies (1:2000, 1 hr; Life Technologies). Nuclei were
visualised with the DNA stain DAPI (5 mg/mL; Sigma) supplemented with the secondary antibody.
Stained coverslips were mounted on glass slides with Slowfade (Life Technologies) and imaged on a
Nikon Eclipse Ti-U inverted fluorescent microscope using 100x oil objective. Images were analysed
using Nikon NIS-Elements imaging software.
Invasion assay
Parasites were treated with 50 nM rapamycin for 4 hr and after replacing the medium allowed to
grow for 24 hr. Red/green invasion assays were then performed. Parasites were lysed in an invasion
non-permissive buffer, Endo buffer (44.7 mM K2SO4, 10 mM MgSO4, 106 mM sucrose, 5 mM
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glucose, 20 mM Tris–H2SO4, 3.5 mg/mL BSA, pH 8.2). 250 mL of 8E5 parasites/mL in Endo buffer
were added to each well of a 24-well flat-bottom plate (Falcon) containing a coverslip with a conflu-
ent HFF monolayer. The plates were spun at 129 x g for 1 min at 37˚C to deposit parasites onto the
monolayer. The Endo buffer was gently removed and replaced with invasion permissive medium (1%
FBS/DMEM). Parasites were allowed to invade for 15 min at 37˚C, after which the monolayer was
gently washed with PBS and fixed with 3% formaldehyde for 15 min at room temperature. Extracel-
lular (attached) parasites were stained with mouse anti-Toxoplasma (TP3) (1:1000; Abcam) and goat
anti-mouse Alexa Fluor 488 before permeabilisation (0.2% Triton X-100/PBS) and detection of intra-
cellular (invaded) parasites with rabbit anti-TgCAP (1:2000; [Hunt et al., 2019]) and goat anti-rabbit
Alexa Fluor 594. For each replicate, at least five random fields were imaged with a 40x objective.
Three independent experiments were performed in duplicate. The number of intracellular (594+/
488-) and extracellular (594+/488+) parasites was determined by counting, in a blinded fashion, at
least 275 parasites per strain. The parasite counts in the MIC7 iKO and cMut lines were normalised
to the cWT, and results were statistically tested with a one-way ANOVA with Dunnett’s multiple
comparison test in GraphPad Prism 8. The data are presented as mean ± SD. For estimation of the
parasite attachment efficiency, the number of all (594+) parasites was used and the results were sta-
tistically tested as above.
Large scale automated invasion assay
Cell Invasion - HFFs were seeded at a density of 2E4 cells per well into 96-well plate and cultivated
in complete medium at 37˚C and 5% CO2 for 24 hr to allow for sub-confluence. 5E6 to E7 parasites
were collected upon spontaneous egress from synchronously infected HFF monolayers. The superna-
tant was centrifuged at higher speed (900 x g, 7 min) to collect parasites that were gently suspended
in 2 mL of complete medium before counting. 2.5E5 parasites were added to each well. To synchro-
nize invasion, the 96-well plate was centrifuged (300 x g, 3 min) and incubated for 30 min at 37˚C
and 5% CO2. After gentle aspiration, invasion was stopped by addition of 3.2% paraformaldehyde
(PFA) in PBS, pH 7.5 (20 min).
Parasite staining - immunostaining was performed first under conditions that did not permeabilise
the HFF cells to allow discriminating between the extracellular and intracellular parasites. Fixed cell
samples were incubated in 2%BSA/PBS as a blocking buffer (BB) for 20 min. Extracellular tachyzoites
were selectively stained using mouse anti-TgSAG1(TP3) (1 mg/mL stock, 1:600, 40 min; Novocastra)
followed by Alexa Fluor 488-conjugated highly cross-adsorbed (HCA) anti-mouse antibody (2 mg/mL
stock, 1:800, 1 hr). The excess of reagents was washed off with PBS and cells were permeabilised
(0.2% Triton X-100/PBS, 10 min) prior to incubation in BB and the second staining step using anti-
TgSAG1 (1 mg/mL stock, 1:600, 1 hr) but followed by Alexa Fluor 594-conjugated HCA anti-mouse
antibody (2 mg /ml stock, 1:800, 1 hr). Cell nuclei were stained with 500 nM DAPI and the 96 well
plates were automatically scanned to quantify the average number of cells per well. The nuclei of
parasites are detected by blue fluorescence whereas the intracellular tachyzoites by red fluorescence
and the extracellular ones by yellow fluorescence (as the result of green and red fluorescence).
Quantification - samples were automatically scanned at a magnification of 20x under an Olympus
ScanR automated inverted microscope. Images were acquired for five wells per parasite strain for
each invasion assay, with 16 randomly scanned fields per well and further processed with ScanR soft-
ware. ScanRAnalysis includes algorithms to provide automated cell nuclei segmentation following
signal-to-noise ratio optimisation and accurate cell surface mask definition. To identify intracellular
(red) over extracellular (yellow) parasites, image subtraction from each channel was automatically
obtained. Data collected allowed determining the total number of intracellular tachyzoites over the
total number of host cells for each well. Three independent assays were carried out, and data were
statistically analysed using a two-tailed Student’s t-test in GraphPad Prism 8. The data are presented
as mean ± SD.
Invasion video microscopy
Preparation of human cells - HFF and Human Bone OsteoSarcoma cells (U2OS) that stably expressed
the GFP-GPI plasma membrane reporter, were seeded at a density of 3E5 cells per 18 mm glass cov-
erslip, previously coated with poly-L-lysine (50 mg/mL). Cells were cultivated in complete medium at
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37˚C and 5% CO2 for 24 hr to allow for 80% confluence. Coverslips were placed in Chamlide cham-
bers (LCI Corp.) and covered with a minimal volume (i.e. 100 mL) of motility buffer (see below).
Preparation of parasites – 2E5 to 4E5 parasites were typically collected upon spontaneous egress
from synchronously infected HFF monolayers. 150 mL of this suspension were mixed with 5 mL of
Hanks’ Balanced Salt Solution (HBSS) supplemented with 0.2% FCS. After centrifugation (900 x g, 7
min), parasites were resuspended in 200 mL of motility buffer (HBSS supplemented with 1% FCS and
0.5 mM CaCl2 to reach about 1.6 mM CaCl2 final). Typically, 30 to 40 mL of the suspension were
added to the cells on the coverslip immobilized in the chamber, to avoid parasite overcrowding dur-
ing recording.
Video recording of the tachyzoite behaviour - the recording chamber that accommodates the
coverslips was installed on an Eclipse Ti inverted confocal microscope (Nikon) to perform time-lapse
video microscopy, with a temperature and CO2-controlled stage (LCI Corp.). The microscope was
also equipped with a CMOS camera and a CSU X1 spinning disk (Yokogawa, Roper Scientific). The
microscope was piloted using MetaMorph software (Universal Imaging Corporation, Roper Scien-
tific). Similar parameters for image acquisition were used throughout each independent experiment.
Time of invasion was estimated for each tachyzoite using MetaMorph time scale between the
moment of contact between parasite apex (i.e. conoid) and host cell membrane until the tachyzoite
has fully passed through the cell-zoite junction. Time of failed invasion was quantified using the
same software, once again between the time of apical contact to those of body withdrawal and
detachment, or the moment the tachyzoite did not perform any movement.
Gliding assays
Freshly egressed parasites of each genetic background were prepared as for the video recording
assays. About 2 to 4E5 tachyzoites in 300 mL of motility buffer were deposited on 12 mm glass cov-
erslip, previously coated with poly-L-lysine (as above) and placed in a 24 well plate. Parasites were
gently centrifuged (200 x g, 3 min) to ensure rapid contact with the coverslip and then allowed to
glide for 10–15 min at 37˚C and 5% CO2. Motile activity was checked under microscope after a few
first minutes. At the end of this period, the samples were fixed after gentle aspiration of the liquid
by the addition of 3.2% PFA in PHEM pH 7.5 (20 min). Trails left by gliding parasites and parasite
surface were stained after a blocking step (2% BSA/PBS, 30 min) with mouse anti-TgSAG1 antibody
(1 mg/mL stock, 1:600, 2 hr) and Alexa Fluor 488-conjugated HCA anti-mouse antibody (2 mg/mL
stock, 1:800, 2 hr). Cell nuclei were stained with 500 nM DAPI and mounted in Mowiol. Images of
trails and tachyzoites were captured under the fluorescent ApoTome two microscope (Zeiss) using
appropriate set of filters, the Zen software (Zeiss) and a z step of 0.3 mm. Image stacks were further
processed with FIJI (Schindelin et al., 2012) and Photoshop.
Immunofluorescence of successful and failed invasions
MIC7 iKO parasites were treated with DMSO or rapamycin and were prepared as described for the
video recording assays. Approximately 8E5 tachyzoites in 300 mL of motility buffer were deposited
on 12 mm glass coverslip previously coated with poly-L-lysine (as above) and placed in a 24 well
plate. Tachyzoites were gently centrifuged (300 x g, 3 min) to ensure rapid contact with the host cell
(non-fluorescent HFF and GFP-GPI expressing U2OS cells) and allowed to invade for 2 to 4 min peri-
ods at 37˚C and 5% CO2. Samples were immediately fixed in 3.2% PFA in PHEM pH 7.5 (20 min)
prior to be processed for IFA. Blocking step and anti-TgSAG1 staining were performed as for the
gliding assay except that the incubation with SAG1 primary antibody and Alexa Fluor 633-conju-
gated secondary antibody was reduced to 30 min. After SAG1 staining, the HFF-tachyzoite samples
were permeabilised with (0.2% Triton X-100/PBS, 5 min) prior to a second step of blocking. MIC7
labelling was performed using rabbit anti-HA (clone C29F4), (1:800, 2 hr; Cell Signaling) followed by
Alexa Fluor 488-conjugated HCA anti-rabbit antibody (2 mg/mL stock, 1:800, 2 hr).
MIC7 dimerisation
HFF monolayers infected with parasites from the DiCre, MyccWT and MyccMut lines were washed
with cold PBS and lysed in IP buffer (50 mM Tris, 150 mM NaCl, 0.2% Triton-X100, pH7.5) supple-
mented with protease inhibitors (Roche Diagnostics) for 30 min on ice. The lysates were then centri-
fuged (5000 x g, 20 min, 4˚C), the supernatants collected and incubated with 20 mL of a-HA-
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conjugated agarose beads (Millipore) on a rotating wheel at 4˚C. After 3 hr the supernatant was
removed and beads washed 3x with IP buffer. Protein elution from beads was performed with SDS
sample loading buffer and boiling at 95˚C for 10 min. Input, IP and supernatant samples for each
tested parasite line were then analysed by SDS-PAGE and western blotting.
Microneme secretion assay
Parasites from MIC7 iKO line were treated with DMSO or rapamycin (50 nM, 4 hr). After 24 hr incu-
bation parasites were syringe lysed in DMEM at room temperature and collected by centrifugation
(800 x g, 4˚C, 10 min). Pellets were resuspended in Ringer’s buffer (155 mM NaCl, 3 mM KCl, 2 mM
CaCl2, 1 mM MgCl2, 3 mM NaH2PO4, 10 mM HEPES, 10 mM glucose) supplemented with BIPPO (50
mM) or vehicle and microneme secretion was induced at 37˚C for 20 min. Following this incubation
step the parasites were placed on ice and pelleted (1000 x g, 5 min, 4˚C). The pellet was kept on ice
while the supernatant was re-pelleted (2000 x g, 5 min, 4˚C). The final supernatant, containing the
excreted secreted antigens, and pellet fractions were resuspended in sample loading buffer prior to
SDS-PAGE and western blotting.
Shedding assays
Shedding tests during egress for MyccWT and MyccMut lines were performed exactly as described in
microneme secretion assay.
To test for MIC7 shedding upon invasion, parasites from the iKO, MyccWT and MyccMut lines were
treated with DMSO or rapamycin (50 nM, 4 hr). After 24 hr incubation parasites were syringe lysed
in cold DMEM and spun (300 x g, 3 min, 4˚C) onto PBS washed HFF monolayers in a 6-well plate (Fal-
con). The plate was then incubated at 37˚C to facilitate invasion. After 1 hr the plate was placed on
ice, the supernatant was gently aspirated off and spun down (700 x g, 10 min, 4˚C) to remove any
aspirated parasites. Proteins were precipitated out by the addition of cold trichloroacetic acid (10%
v/v) on ice (30 min). Samples were centrifuged (17,000 x g, 20 min, 4˚C), washed with 300 mL of cold
acetone and air dried. The infected monolayers were scraped in 0.5 mL cold PBS and collected by
centrifugation (17,000 x g, 20 min, 4˚C). Both pellet and supernatant samples were resuspended in
sample loading buffer prior to SDS-PAGE and western blotting.
Proteinase K protection assay
Parasites from MyccWT and MyccMut lines were treated with rapamycin (50 nM, 4 hr) followed by
YnMyr (25 mM, 16 hr). Parasites were then syringe lysed in DMEM at room temperature and col-
lected by centrifugation (800 x g, 10 min, 4˚C). Pellets were resuspended in 1.7 mL cold SoTE buffer
(0.6 M sorbitol, 20 mM Tris–HCl (pH 7.5), and 2 mM EDTA) and split into three tubes (0.5 mL each)
per tested parasite line. Tubes 2 and 3 were permeabilised with 0.01% cold Digitonin (Sigma-
Aldrich) in SoTE. Samples were carefully mixed by inversion and incubated on ice (10 min) prior to
centrifugation (1000 x g, 10 min, 4˚C). Supernatant was discarded. Pellets were resuspended in 0.5
mL cold SoTE and 8 mg of Proteinase K (Sigma-Aldrich) were added to tube 3. All tubes were gently
inverted and incubated on ice (30 min). Proteinase K was inactivated by addition of ice cold trichloro-
acetic acid to a final concentration of 10% v/v on ice (30 min). Samples were centrifuged (17,000 x g,
20 min, 4˚C), washed with 300 mL of cold acetone and air dried prior to SDS-PAGE and western
blotting.
Rhoptry secretion assay
Parasites from iKO, MyccWT and MyccMut lines were treated with 50 nM rapamycin or an equivalent
volume of vehicle (DMSO) for 4 hr after which the medium was replaced and the parasites allowed
to grow for 24 hr. Parasites were harvested by syringe lysis, counted, and treated with 1 mM Cyto-
chalasin D (Sigma) for 10 min at room temperature. 500,000 parasites from each condition were
seeded onto confluent HFF monolayers grown in chambered coverslip slides (ibidi) and allowed to
settle for 10 min on ice. The slides were spun down (250 x g, 1 min, 4˚C) then transferred to a 37˚C
water bath for 20 min to initiate rhoptry secretion. The chambers were washed 3x with PBS then
fixed with ice-cold methanol at  20˚C for 8 min and washed 3x with PBS. Fixed cells were permeabi-
lised with 0.1% Triton X-100 in PBS for 15 min then blocked with 3% BSA in PBS for 1 hr. Cells were
then incubated with rabbit anti-phospho-Stat6 (1:600; Cell Signaling) and mouse anti-Toxoplasma
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(TP3) (1:1000; Abcam) primary antibodies for 1 hr. After 3x washes with PBS, cells were incubated
with goat anti-rabbit Alexa Fluor 594 (1:2000; Life Technologies) and goat anti-mouse Alexa Fluor
488 (1:2,000; Life Technologies) secondary antibodies and 5 mg/mL DAPI (Sigma) for 1 hr followed
by 3x washes with PBS. Images were obtained using a Nikon Eclipse Ti-U inverted fluorescent micro-
scope using a 20x objective and analysed using FIJI software. 5 fields of view per condition were
analysed in three independent experiments. The number of pSTAT6 positive HFFs was normalised
to the total number of HFFs, and results were statistically tested with a two-way ANOVA with Sidak’s
multiple comparison test in GraphPad Prism 8. The data are presented as mean ± SD.
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Data availability
All data generated or analysed during this study are included in the manuscript and supporting files.
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Frénal K, Kemp LE, Soldati-Favre D. 2014. Emerging roles for protein S-palmitoylation in Toxoplasma biology.
International Journal for Parasitology 44:121–131. DOI: https://doi.org/10.1016/j.ijpara.2013.09.004, PMID: 241
84909
Gaji RY, Johnson DE, Treeck M, Wang M, Hudmon A, Arrizabalaga G. 2015. Phosphorylation of a myosin motor
by TgCDPK3 facilitates rapid initiation of motility during Toxoplasma gondii egress. PLOS Pathogens 11:
e1005268. DOI: https://doi.org/10.1371/journal.ppat.1005268, PMID: 26544049
Gajria B, Bahl A, Brestelli J, Dommer J, Fischer S, Gao X, Heiges M, Iodice J, Kissinger JC, Mackey AJ, Pinney
DF, Roos DS, Stoeckert CJ, Wang H, Brunk BP. 2008. ToxoDB: an integrated Toxoplasma gondii database
resource. Nucleic Acids Research 36:D553–D556. DOI: https://doi.org/10.1093/nar/gkm981, PMID: 18003657
Broncel et al. eLife 2020;9:e57861. DOI: https://doi.org/10.7554/eLife.57861 35 of 38
Research article Microbiology and Infectious Disease
Garrison E, Treeck M, Ehret E, Butz H, Garbuz T, Oswald BP, Settles M, Boothroyd J, Arrizabalaga G. 2012. A
forward genetic screen reveals that calcium-dependent protein kinase 3 regulates egress in Toxoplasma. PLOS
Pathogens 8:e1003049. DOI: https://doi.org/10.1371/journal.ppat.1003049, PMID: 23209419
Goder V, Spiess M. 2001. Topogenesis of membrane proteins: determinants and dynamics. FEBS Letters 504:
87–93. DOI: https://doi.org/10.1016/S0014-5793(01)02712-0, PMID: 11532438
Goldberg J. 1998. Structural basis for activation of ARF GTPase: mechanisms of guanine nucleotide exchange
and GTP-myristoyl switching. Cell 95:237–248. DOI: https://doi.org/10.1016/s0092-8674(00)81754-7, PMID: 97
90530
Gordon JI, Duronio RJ, Rudnick DA, Adams SP, Gokel GW. 1991. Protein N-myristoylation. The Journal of
Biological Chemistry 266:8647–8650. PMID: 2026581
Heal WP, Wright MH, Thinon E, Tate EW. 2012. Multifunctional protein labeling via enzymatic N-terminal
tagging and elaboration by click chemistry. Nature Protocols 7:105–117. DOI: https://doi.org/10.1038/nprot.
2011.425
Howard BL, Harvey KL, Stewart RJ, Azevedo MF, Crabb BS, Jennings IG, Sanders PR, Manallack DT, Thompson
PE, Tonkin CJ, Gilson PR. 2015. Identification of potent phosphodiesterase inhibitors that demonstrate cyclic
nucleotide-dependent functions in apicomplexan parasites. ACS Chemical Biology 10:1145–1154. DOI: https://
doi.org/10.1021/cb501004q, PMID: 25555060
Hunt A, Russell MRG, Wagener J, Kent R, Carmeille R, Peddie CJ, Collinson L, Heaslip A, Ward GE, Treeck M.
2019. Differential requirements for cyclase-associated protein (CAP) in actin-dependent processes of
Toxoplasma gondii. eLife 8:e50598. DOI: https://doi.org/10.7554/eLife.50598, PMID: 31577230
Hutton JA, Goncalves V, Brannigan JA, Paape D, Wright MH, Waugh TM, Roberts SM, Bell AS, Wilkinson AJ,
Smith DF, Leatherbarrow RJ, Tate EW. 2014. Structure-based design of potent and selective leishmania N-
myristoyltransferase inhibitors. Journal of Medicinal Chemistry 57:8664–8670. DOI: https://doi.org/10.1021/
jm5011397, PMID: 25238611
Huynh MH, Rabenau KE, Harper JM, Beatty WL, Sibley LD, Carruthers VB. 2003. Rapid invasion of host cells by
Toxoplasma requires secretion of the MIC2-M2AP adhesive protein complex. The EMBO Journal 22:2082–
2090. DOI: https://doi.org/10.1093/emboj/cdg217, PMID: 12727875
Huynh MH, Carruthers VB. 2009. Tagging of endogenous genes in a Toxoplasma gondii strain lacking Ku80.
Eukaryotic Cell 8:530–539. DOI: https://doi.org/10.1128/EC.00358-08, PMID: 19218426
Jacot D, Soldati-Favre D. 2012. Does protein phosphorylation govern host cell entry and egress by the
apicomplexa? International Journal of Medical Microbiology 302:195–202. DOI: https://doi.org/10.1016/j.ijmm.
2012.07.012
Jia Y, Benjamin S, Liu Q, Xu Y, Dogga SK, Liu J, Matthews S, Soldati-Favre D. 2017a. Toxoplasma gondii immune
mapped protein 1 is anchored to the inner leaflet of the plasma membrane and adopts a novel protein fold.
Biochimica Et Biophysica Acta (BBA) - Proteins and Proteomics 1865:208–219. DOI: https://doi.org/10.1016/j.
bbapap.2016.11.010
Jia Y, Marq JB, Bisio H, Jacot D, Mueller C, Yu L, Choudhary J, Brochet M, Soldati-Favre D. 2017b. Crosstalk
between PKA and PKG controls pH-dependent host cell egress of Toxoplasma gondii. The EMBO Journal 36:
3250–3267. DOI: https://doi.org/10.15252/embj.201796794, PMID: 29030485
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